Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription Articles published in Schizophr Res Retrieve available abstracts of 680 articles: HTML format

Single Articles

October 2025
1. NOVACEK DM, Subotnik KL, Ventura J, Casaus LR, et al
   Corrigendum to "Positive symptoms and medication adherence in response to oral versus long-acting injectable risperidone in black, latino, and white first-episode psychosis patients" [Schizophr Res. (2025) 160-166].
   Schizophr Res. 2025 Oct 3:S0920-9964(25)00336.
   PubMed    
   
   
   September 2025
2. HIRJAK D, Volkmer S, Pokorny V, Mittal VA, et al
   Advancing the sensori-/psychomotor domain in schizophrenia spectrum disorders: From clinical observation to translational innovation.
   Schizophr Res. 2025;285:185-195.
   PubMed     Abstract available
   
   
   
3. MOLLON J, Lanzagorta N, Mathias SR, Rodrigue A, et al
   The burden of early onset psychosis: Diagnostic complexity, high comorbidity, and poor functioning in patients and their relatives.
   Schizophr Res. 2025;285:165-174.
   PubMed     Abstract available
   
   
   
4. CAROL EE, Rodriguez J, Guvenek-Cokol PE, Kim HJ, et al
   Learning health systems in early interventions for psychosis: Establishing consumer voices in clinical high-risk for psychosis care.
   Schizophr Res. 2025;285:149-154.
   PubMed     Abstract available
   
   
   
5. DAMME KSF
   The hippocampus: At the nexus of risk and resilience for schizophrenia.
   Schizophr Res. 2025;285:141-148.
   PubMed    
   
   
   
6. KESHAVAN MS, Good M
   Rethinking psychosis: Time to retire "organic", "idiopathic" and "secondary"?
   Schizophr Res. 2025;285:132-133.
   PubMed    
   
   
   
7. XIE S, Glassman M, Vyas G, Nwulia E, et al
   Longitudinal analysis of absolute neutrophil count (ANC) variability and neutropenia incidence in African American schizophrenia patients by ACKR1 genotype.
   Schizophr Res. 2025;285:124-131.
   PubMed     Abstract available
   
   
   
8. PANTOJI M, Balachander S, Prajapati P, Arumugham SS, et al
   Does adjunctive electro-convulsive therapy improve the speed of treatment response in schizophrenia? A systematic review and week-by-week meta-analyses of controlled clinical trials.
   Schizophr Res. 2025;285:114-123.
   PubMed     Abstract available
   
   
   
9. WEZENBERG BN, Koster M, van Wingen G, de Haan L, et al
   Association between sleep disturbances and gray matter volume in individuals at clinical high-risk for psychosis and healthy controls: A longitudinal MRI study (NAPLS-3).
   Schizophr Res. 2025;285:105-113.
   PubMed     Abstract available
   
   
   
10. FLORES AT, Barrio C, Yu L, Harvey PD, et al
    Psychometric validation of social cognition measures in U.S. Hispanic individuals with schizophrenia.
    Schizophr Res. 2025;285:95-104.
    PubMed     Abstract available
    
    
    
11. ORAKI KOHSHOUR M, Barth TK, Huber C, Klingl A, et al
    Comparing the proteome profiling of plasma-derived extracellular vesicles in individuals with schizophrenia and healthy controls: a pilot study.
    Schizophr Res. 2025;285:87-94.
    PubMed     Abstract available
    
    
    
12. LIU W, Carnelley KB, Newman-Taylor K
    How does attachment affect help-seeking in people with paranoia and psychosis? The role of emotion regulation, self-stigma, and perceived support.
    Schizophr Res. 2025;285:75-86.
    PubMed     Abstract available
    
    
    
13. ORLOVIC I, Markos IS, Blazekovic I, Peitl V, et al
    Thalamic hyperperfusion in early schizophrenia: Associations with cognitive deficits and negative symptoms.
    Schizophr Res. 2025;285:60-69.
    PubMed     Abstract available
    
    
    
14. HORSDAL HT, Jensen AS, Antonsen S, Pedersen MG, et al
    Examining relationships between the Danish Composite Deprivation Index and risk of developing schizophrenia: A national multilevel analysis.
    Schizophr Res. 2025;285:52-59.
    PubMed     Abstract available
    
    
    
15. IVLEVA EI, Palka JM, Bobilev AM, Fang Y, et al
    Hippocampal subfield activity in schizophrenia: Effects of the disease course.
    Schizophr Res. 2025;285:39-51.
    PubMed     Abstract available
    
    
    
16. XU M, Gao D, Hu A, Qian H, et al
    Social isolation and its influencing factors among family caregivers of individuals with schizophrenia: A social-ecological systems theory perspective.
    Schizophr Res. 2025;285:30-38.
    PubMed     Abstract available
    
    
    
17. HAMMER LA, Springfield CR, Russell MT, Twilbeck B, et al
    Minority stress and schizophrenia-like experiences in sexual and gender minority adults.
    Schizophr Res. 2025;285:27-29.
    PubMed    
    
    
    
18. BAREIS N, Wang Y, Olfson M, Gerhard T, et al
    Machine learning for novel phenotyping in schizophrenia.
    Schizophr Res. 2025;285:19-26.
    PubMed     Abstract available
    
    
    
19. SU Q, Liu Y, Ji L, Sun X, et al
    The relationship between age of onset, peripheral plasma protein markers and social cognition in first-episode drug-naive schizophrenia.
    Schizophr Res. 2025;285:11-18.
    PubMed     Abstract available
    
    
    
20. HSU JW, Chen LC, Lin WC, Bai YM, et al
    Reduced levels of vascular endothelial growth factor were associated with psychopathology in youth with first-episode schizophrenia.
    Schizophr Res. 2025;284:269-274.
    PubMed     Abstract available
    
    
    
21. NKIRE N, Kingston T, Kinsella A, Russell V, et al
    Prediction of long-term outcome by duration of the psychosis prodrome: Mixed effects models reveal continuity across 7 years but variation across quartile splits.
    Schizophr Res. 2025;284:263-268.
    PubMed     Abstract available
    
    
    
22. HOTER ISHAY G, Roe D
    Patterns of service utilization and its relation to outcome in a first-episode psychosis program.
    Schizophr Res. 2025;284:256-262.
    PubMed     Abstract available
    
    
    
23. WATERS Z, Ohan JL, Perry Y, Baird S, et al
    Perceived stigma and self-stigma in young people at ultra-high risk for psychosis: Associations with identity-related, psychological and functional outcomes.
    Schizophr Res. 2025;284:248-255.
    PubMed     Abstract available
    
    
    
24. INO H, Akabayashi A, Takimoto Y, Mori K, et al
    Effect of social resources on readmission prevention and the influence of informal coercion in acute schizophrenia: a retrospective quasi-experimental cohort study.
    Schizophr Res. 2025;285:1-10.
    PubMed     Abstract available
    
    
    
25. SANJARI MOGHADDAM H, Aarabi MH, Kiani I, Cattarinussi G, et al
    Microstructural alterations of the corpus callosum in affective and non-affective early psychosis: A diffusion magnetic resonance imaging study.
    Schizophr Res. 2025;284:237-247.
    PubMed     Abstract available
    
    
    
26. NASHASHIBI L, Harlev D, Grinapol S, Karny T, et al
    Ethnic bias in risk assessment of patients with early-onset first episode psychosis.
    Schizophr Res. 2025;284:231-236.
    PubMed     Abstract available
    
    
    
27. LIU D, Choi KW, Lizano P, Yuan W, et al
    Construction of extra-large scale screening tools for risks of severe mental illnesses using real world healthcare data.
    Schizophr Res. 2025;283:59-66.
    PubMed     Abstract available
    
    
    
28. FASSLER L, Moritz S, Schories F, Bajbouj M, et al
    Effects of an unguided self-help intervention for distressing auditory verbal hallucinations in a heterogenous sample of voice hearers: A randomized controlled trial and explorative cluster analysis.
    Schizophr Res. 2025;283:36-47.
    PubMed     Abstract available
    
    
    August 2025
29. SALEM D, Clark SM, Roche DJO, Singh NJ, et al
    T cells are associated with negative symptoms in persons with anti-gliadin antibody positive schizophrenia and related disorders.
    Schizophr Res. 2025;284:222-230.
    PubMed     Abstract available
    
    
    
30. NIU Z, Jia L, Tian L, Liu Y, et al
    Evaluating the abnormal neural variability in schizophrenia: A TMS-EEG study.
    Schizophr Res. 2025;284:214-221.
    PubMed     Abstract available
    
    
    
31. KITTLESON AR, Woodward ND, McHugo M, Liu J, et al
    A two-year longitudinal investigation of insula subregional cortical thickness and surface area in early psychosis.
    Schizophr Res. 2025;284:204-213.
    PubMed     Abstract available
    
    
    
32. HUMBLE MB, Mobarrez F, Eklund D, Bejerot S, et al
    Aquaporin-4 positive extracellular vesicles and cytokines in cerebrospinal fluid in schizophrenia and obsessive-compulsive disorder, and associations with peripheral cytokines.
    Schizophr Res. 2025;284:195-203.
    PubMed     Abstract available
    
    
    
33. EMPSON LA, Golay P, Baumann PS, Favrod J, et al
    Refining targets for urban remediation in early psychosis.
    Schizophr Res. 2025;284:186-194.
    PubMed     Abstract available
    
    
    
34. BADENOCH JB, Rickards H, McCutcheon RA, Nair A, et al
    Psychosis in Huntington's disease: a review and comparison with schizophrenia.
    Schizophr Res. 2025;284:175-185.
    PubMed     Abstract available
    
    
    
35. NOVACEK DM, Subotnik KL, Ventura J, Casaus LR, et al
    Positive symptoms and medication adherence in response to oral versus long-acting injectable risperidone in black, latino, and white first-episode psychosis patients.
    Schizophr Res. 2025;284:160-166.
    PubMed     Abstract available
    
    
    
36. BAGROWSKA P, Wannan C, Polari A, Yuen HP, et al
    Therapy process factors in early psychosis: The effect of working alliance on clinical symptoms and cognitive biases in Ultra High Risk young people.
    Schizophr Res. 2025;284:151-159.
    PubMed     Abstract available
    
    
    
37. KARACAM DOGAN M, Fusar-Poli L, Arias-Magnasco A, Pries LK, et al
    Examining psychological protective mechanisms as moderators of the association between autistic traits and psychosis expression in a general population twin sample.
    Schizophr Res. 2025;284:133-140.
    PubMed     Abstract available
    
    
    
38. SURAJ-PRAZMOWSKA J, Marczyk B, Smierciak N, Szwajca M, et al
    Young first-episode psychosis patients exhibit impaired microvascular function in the skin and low systemic nitric oxide availability, independent of classical cardiovascular risk factors.
    Schizophr Res. 2025;283:188-199.
    PubMed     Abstract available
    
    
    
39. MEYER-KALOS PS, Neill M, Owens G, Russell M, et al
    NAV-FS: A first episode psychosis services fidelity scale adapted for the NAVIGATE model.
    Schizophr Res. 2025;284:125-132.
    PubMed     Abstract available
    
    
    
40. TAYFUR SN, Hazan H, Li F, Song Z, et al
    The potential of AI for scale development: A self-report psychosis symptoms measure using ChatGPT.
    Schizophr Res. 2025;284:111-113.
    PubMed    
    
    
    
41. HUANG D, Xiang Z, Liu K, Lv L, et al
    Disrupted static and dynamic small-world brain network topologies in patients with schizophrenia.
    Schizophr Res. 2025;284:101-110.
    PubMed     Abstract available
    
    
    
42. ZHANG J, Zhang G, Zhao Q, Peng Y, et al
    Genetic overlap between household income and psychiatric disorders.
    Schizophr Res. 2025;282:95-104.
    PubMed     Abstract available
    
    
    
43. MCBRIDE LE, Gentry MM, Pinkham AE, Granholm E, et al
    The intersection of structural social factors, loneliness, and social activity in individuals with psychotic disorders.
    Schizophr Res. 2025;282:76-84.
    PubMed     Abstract available
    
    
    
44. WILDGRUBER D, Hesse K, Eckstein KN, Richter J, et al
    Combining cognitive behavioral therapy and group training for social skills and cognition to improve negative symptoms in patients with psychotic disorders: a randomized controlled pilot trial.
    Schizophr Res. 2025;282:38-48.
    PubMed     Abstract available
    
    
    July 2025
45. JI YS, Liu FY, Wei Y, Liu YF, et al
    Sex differences in the peripheral blood transcriptome and their associations with neuroimaging and cognition in schizophrenia.
    Schizophr Res. 2025;284:77-85.
    PubMed     Abstract available
    
    
    
46. LIMA TSA, Corsi-Zuelli F, Souza AJ, Colodete DAE, et al
    Low-dose methotrexate as a potential treatment for schizophrenia via astrocytic and neuroimmune modulation.
    Schizophr Res. 2025;284:67-76.
    PubMed     Abstract available
    
    
    
47. STRAUSS GP, Luther L, Raugh IM, Zhang S, et al
    Environmental deprivation is associated with reward processing impairments and negative symptoms in schizophrenia.
    Schizophr Res. 2025;284:59-66.
    PubMed     Abstract available
    
    
    
48. FANSHAWE JB, Lawrence R, Ghanem DA, Pauli L, et al
    The role of the electroencephalogram (EEG) in determining the aetiology of psychosis: a systematic review and meta-analysis of diagnostic test accuracy.
    Schizophr Res. 2025;284:48-58.
    PubMed     Abstract available
    
    
    
49. DU A, Kennedy L, Addington J, Bearden CE, et al
    Victimization and engagement with the legal system among individuals at clinical high risk (CHR) for psychosis.
    Schizophr Res. 2025;284:7-15.
    PubMed     Abstract available
    
    
    
50. DONDE C, Pereira M, Nalborczyk L, Roux P, et al
    Characterizing early auditory deficits in schizophrenia using drift-diffusion modeling.
    Schizophr Res. 2025;284:23-31.
    PubMed     Abstract available
    
    
    
51. AKPANEKPO EI, Chowdhury NZ, Butler T
    Early mental health treatment and reoffending among justice-involved youth diagnosed with psychosis.
    Schizophr Res. 2025;284:16-22.
    PubMed     Abstract available
    
    
    
52. CATTARINUSSI G, Sambataro F, Dazzan P
    Climate change, air pollution, and schizophrenia: Moving the field forward.
    Schizophr Res. 2025;284:1-6.
    PubMed    
    
    
    
53. ANTAKI F, Kerexeta-Sarriegi J, Reis APR, Zhu Z, et al
    The association of retinal age gap with schizophrenia: a cross-sectional analysis.
    Schizophr Res. 2025;283:180-187.
    PubMed    
    
    
    
54. HU H, Xia M, Chen L, Hu Y, et al
    Hippocampal perfusion abnormalities and treatment effects in acute phase of first-episode schizophrenia.
    Schizophr Res. 2025;283:173-179.
    PubMed     Abstract available
    
    
    
55. PELIZZA L, Leuci E, Quattrone E, Palmisano D, et al
    Autism-spectrum traits in First Episode Psychosis: Psychopathological and prognostic considerations from a 2-year follow-up study.
    Schizophr Res. 2025;283:163-172.
    PubMed     Abstract available
    
    
    
56. KHANDKER R, Mohit B, Fonseca E, Fleming S, et al
    Treatment discontinuation and switching of antipsychotics among adult patients with schizophrenia in the United States.
    Schizophr Res. 2025;283:152-162.
    PubMed     Abstract available
    
    
    
57. CARPENDALE EJ, Bell MC, Cullen AE, Dickson H, et al
    Differentiation of childhood risk profiles for schizophrenia according to the development of verbal and performance intelligence.
    Schizophr Res. 2025;283:144-151.
    PubMed     Abstract available
    
    
    
58. YAO B, Hall MH, Tusuzian E, Cohen B, et al
    Childhood adverse events and their association with psychotic symptoms and quality of life in young adults with first episode psychosis and unaffected siblings.
    Schizophr Res. 2025;283:137-143.
    PubMed     Abstract available
    
    
    
59. DAS N, Choudhary S, Nagendra S, Dutt S, et al
    Digital phenotyping correlates of cognitive performance in schizophrenia spectrum disorders from a longitudinal study.
    Schizophr Res. 2025;283:130-136.
    PubMed     Abstract available
    
    
    
60. SAKURAI T, Birnbaum M, Chua YHV, Isa T, et al
    Ecological and momentary assessment and intervention for schizophrenia: Use of smartphone apps and video games.
    Schizophr Res. 2025;283:122-129.
    PubMed     Abstract available
    
    
    
61. VILA-BADIA R, Espinosa V, Colomer-Salvans A, Serra-Arumi C, et al
    Childhood sexual abuse in first-episode psychosis: The relevance in cognitive bias.
    Schizophr Res. 2025;283:98-106.
    PubMed     Abstract available
    
    
    
62. ZHANG T, Yang X, Mu P, Huo X, et al
    Stage-specific computational mechanisms of working memory deficits in first-episode and chronic schizophrenia.
    Schizophr Res. 2025;282:203-213.
    PubMed     Abstract available
    
    
    
63. GELNER H, Krezolek M, Aleksandrowicz A, Piwinska J, et al
    The role of demographic variables in the effectiveness of metacognitive training for psychosis: A meta-analysis.
    Schizophr Res. 2025;283:85-97.
    PubMed     Abstract available
    
    
    
64. FAUVIAUX T, Parisi M, Marin L, Vattier V, et al
    "The second I laid eyes on him I knew": First impressions predict willingness to interact with individuals with schizophrenia.
    Schizophr Res. 2025;283:77-84.
    PubMed     Abstract available
    
    
    
65. SAMANTARAY S, Goyal N, Kesavan M, Venkatasubramanian G, et al
    Impaired corollary discharge as a predictor of reality monitoring deficits in schizophrenia: Implications for auditory verbal hallucinations.
    Schizophr Res. 2025;283:67-76.
    PubMed     Abstract available
    
    
    
66. GUIOMAR R, Catoira B, Castilho P, Baeken C, et al
    Optimisation and development of new tDCS montages to target the cerebellum in schizophrenia: An electrical current modeling study.
    Schizophr Res. 2025;283:48-58.
    PubMed     Abstract available
    
    
    
67. COMPTON MT
    Food and nutrition insecurity among individuals with schizophrenia and related psychotic disorders.
    Schizophr Res. 2025;283:21-26.
    PubMed     Abstract available
    
    
    
68. GIBBS K, McHugo M, Moussa-Tooks A, Woodward ND, et al
    Hippocampal volume in affective and non-affective psychosis.
    Schizophr Res. 2025;283:11-20.
    PubMed     Abstract available
    
    
    
69. PAREDES R, Ferri F, Romei V, Series P, et al
    Increased excitation enhances the sound-induced flash illusion by impairing multisensory causal inference in the schizophrenia spectrum.
    Schizophr Res. 2025;283:1-10.
    PubMed     Abstract available
    
    
    
70. TAYFUR SN, Yoviene Sykes LA, Tek C, Srihari VH, et al
    Utilization of a psychosis consultation service: Early lessons from a statewide initiative.
    Schizophr Res. 2025;282:198-202.
    PubMed     Abstract available
    
    
    
71. HUTTON P, Taylor CDJ, Kelly J, Emsley R, et al
    Accelerating the development of a psychological intervention to restore treatment decision-making capacity in patients with schizophrenia-spectrum disorder: An umbrella trial.
    Schizophr Res. 2025;282:184-197.
    PubMed     Abstract available
    
    
    
72. KIM E, Kim S, Kim SW, Nam BW, et al
    Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs.
    Schizophr Res. 2025;281:180-190.
    PubMed     Abstract available
    
    
    
73. AKERELE CA, Koralnik LR, Lafont E, Gilman C, et al
    Nutrition and brain health: Implications of Mediterranean diet elements for psychiatric disorders.
    Schizophr Res. 2025;281:30-44.
    PubMed     Abstract available
    
    
    
74. DWORKIN A, Jimenez-Jimenez D, Ravenscroft C, Turco F, et al
    TMS-EEG in postictal psychosis of epilepsy.
    Schizophr Res. 2025;282:176-183.
    PubMed     Abstract available
    
    
    June 2025
75. MAJUMDAR V, Kumar PB, Arasappa R, Hegde S, et al
    The mediating influence of serum Klotho levels and the KL-VS heterozygosity on telomere shortening in schizophrenia.
    Schizophr Res. 2025;282:166-175.
    PubMed     Abstract available
    
    
    
76. PARK B, Holbrook A, Rast P, Light GA, et al
    Trial-by-trial ERP-behavior relationships in psychosis: Between- and within-person variability in performance monitoring adjustments.
    Schizophr Res. 2025;282:158-165.
    PubMed     Abstract available
    
    
    
77. CAO BF, Chen HW, Xu ZY, Zhong Q, et al
    Effects of second-generation antipsychotics and long-term atherogenic indices trajectories on metabolic syndrome in patients with schizophrenia.
    Schizophr Res. 2025;282:150-157.
    PubMed     Abstract available
    
    
    
78. ZAVAGLIA E, Joober R, Iyer SN, MacDonald K, et al
    Implementation of a digital measurement-based care approach in an early intervention service for psychosis: the PEPP-Montreal electronic data capture protocol and its alignment with learning health system principles.
    Schizophr Res. 2025;282:141-149.
    PubMed     Abstract available
    
    
    
79. BALDINI V, Pasquino F, De Ronchi D, Plazzi G, et al
    Sleep disturbances in individuals with first episode psychosis and clinical high-risk states: A systematic review.
    Schizophr Res. 2025;282:123-132.
    PubMed     Abstract available
    
    
    
80. O'DONOGHUE B, Eaton S, Lyne J, Thompson A, et al
    Determining the cumulative incidence of treated schizophrenia and predictors of transition in an early intervention for psychosis service.
    Schizophr Res. 2025;282:116-122.
    PubMed     Abstract available
    
    
    
81. MIRHASHEMI E, Bachman P, Krishnan G, Asarnow RF, et al
    Altered neural oscillations are associated with improved working memory performance in schizophrenia following D-cycloserine administration.
    Schizophr Res. 2025;282:85-94.
    PubMed     Abstract available
    
    
    
82. YANG J, Zhu X, Xiao L
    Response to the Letter to the editor: Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study.
    Schizophr Res. 2025;282:114-115.
    PubMed    
    
    
    
83. CORRELL CU, Janetzky W, Brieden A
    Predictors of symptomatic and wellbeing remission in real-world samples of patients living with schizophrenia treated with aripiprazole once-monthly by means of constrained confidence partitioning.
    Schizophr Res. 2025;282:105-113.
    PubMed     Abstract available
    
    
    
84. CHEN B, Ma R, Zhang S, Liu Y, et al
    Letter to the editor: Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study.
    Schizophr Res. 2025;282:74-75.
    PubMed    
    
    
    
85. ZHAI Z, Gao T, Cen H, Li X, et al
    Aberrant prefrontal-hippocampal connectivity of cross-modal associative memory impairment in schizophrenia.
    Schizophr Res. 2025;282:64-73.
    PubMed     Abstract available
    
    
    
86. TISHLER TA, Ellingson BM, Salvadore G, Baker P, et al
    Corrigendum to "Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study" [Schizophr
    Schizophr Res. 2025 Jun 6:S0920-9964(25)00197.
    PubMed    
    
    
    
87. JIANG D, Wang R, Ma D, Tang C, et al
    Prevalence and predictors of metabolic abnormalities and metabolic syndrome among patients with schizophrenia in China.
    Schizophr Res. 2025;282:28-37.
    PubMed     Abstract available
    
    
    
88. PIANI MC, Jandl M, Koenig T, Nordgaard J, et al
    Pre-reflective and reflective abnormalities in cortical midline structures in schizophrenia.
    Schizophr Res. 2025;282:19-27.
    PubMed     Abstract available
    
    
    May 2025
89. HAKAMI MA
    Molecular signatures and emerging therapeutic targets in schizophrenia: A biomarker-centric perspective in psychiatric disorders.
    Schizophr Res. 2025;282:1-18.
    PubMed     Abstract available
    
    
    
90. SCOTT I, Selloni A, Bilgrami Z, Cotter M, et al
    The inventory of psychotic-like anomalous self-experiences (IPASE): Stability and relationships with attenuated psychotic symptoms and remission in individuals at-risk for psychosis.
    Schizophr Res. 2025;281:286-294.
    PubMed     Abstract available
    
    
    
91. SCHOEMAKER G, Mocking RJT, Medema S, Koeter MWJ, et al
    Distribution of red blood cell fatty acids in stable patients with a schizophrenia spectrum disorder and healthy controls.
    Schizophr Res. 2025;281:275-285.
    PubMed     Abstract available
    
    
    
92. SAPERIA S, Prosserman A, Flores Anaya E, Hahn M, et al
    The pleasure expectancies scale (PLEX): A brief measure of expectancies for pleasure in schizophrenia.
    Schizophr Res. 2025;281:268-274.
    PubMed     Abstract available
    
    
    
93. BLOTNER J, Hechinger R, Shenton ME, Coleman MJ, et al
    Negative symptoms, cognition, and community functioning in early psychosis.
    Schizophr Res. 2025;281:260-267.
    PubMed     Abstract available
    
    
    
94. HAU C, Xia W, Ryan S, Firth J, et al
    Smartphone monitoring and digital phenotyping apps for schizophrenia: A review of the academic literature.
    Schizophr Res. 2025;281:237-248.
    PubMed     Abstract available
    
    
    
95. LAVONIUS V, Keltikangas-Jarvinen L, Lyytikainen LP, Hamal Mishra B, et al
    Polygenic risk for schizophrenia predicting Big Five personality traits in individuals without non-affective psychosis.
    Schizophr Res. 2025;281:229-236.
    PubMed     Abstract available
    
    
    
96. SHANKAR S, Ravishankar KS, Krishna Sundari M
    Comparison of Auditory Brainstem Response (ABR) findings in drug-naive schizophrenia patients and healthy comparison subjects.
    Schizophr Res. 2025;281:218-222.
    PubMed     Abstract available
    
    
    
97. CROSSLEY NA, Guloksuz S
    Minimum data standards for schizophrenia and the EnvironmenT (MINDSET) research harmonization exercise.
    Schizophr Res. 2025;281:216-217.
    PubMed    
    
    
    
98. LAKE AM, Reddy IA, Havranek R, Davis LK, et al
    Clinical Characteristics associated with functional seizures in individuals with psychosis.
    Schizophr Res. 2025;281:209-215.
    PubMed     Abstract available
    
    
    
99. LI J, Zhang X, Liu F, Pang L, et al
    Rethinking the core symptom of schizophrenia: An exploration of disorganized thought centrality in psychosis.
    Schizophr Res. 2025;281:201-208.
    PubMed     Abstract available
    
    
    
100. ZHOU H, Yuan X, Xie P, Wang A, et al
     Distinct processing stages of cross-modal conflict in schizophrenia: The role of auditory cortex underactivation.
     Schizophr Res. 2025;281:191-200.
     PubMed     Abstract available
     
     
     
101. APRILE SF, Rodolico A, Di Francesco A, Cutrufelli P, et al
     Exploring weight gain and body image in schizophrenia spectrum disorders: a systematic review of qualitative studies.
     Schizophr Res. 2025;281:177-179.
     PubMed    
     
     
     
102. GAMA-MARQUES J
     Still regarding the potential value of unconjugated bilirubin (UCB) as a biomarker candidate for schizophrenia and schizoaffective psychoses.
     Schizophr Res. 2025;281:175-176.
     PubMed     Abstract available
     
     
     
103. LING L, Wang M, Du W, Wang J, et al
     Development and validation of a neutrophil-lymphocyte ratio-based nomogram for suicidal ideation in first-episode drug-naive schizophrenia patients: A large-scale cross-sectional study.
     Schizophr Res. 2025;281:164-174.
     PubMed     Abstract available
     
     
     
104. CAMPBELL ML, Odokonyero R, Akena D, Alemayehu M, et al
     Sociodemographic influences on substance use in psychosis in an African cohort.
     Schizophr Res. 2025;281:157-163.
     PubMed     Abstract available
     
     
     
105. MEROLA GP, Patti A, Catania G, Boy OB, et al
     Phenomenological psychopathology meets machine learning: A multicentric retrospective study (Mu.St.A.R.D.) targeting the role of Aberrant Salience assessment in psychosis detection.
     Schizophr Res. 2025;281:147-156.
     PubMed     Abstract available
     
     
     
106. JANG YJ, Yassin W, Mesholam-Gately R, Gershon ES, et al
     Corrigendum to "Jang YJ, et al. Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics" [Schizophr Res. 276 (2025) 88-96 10.1016/j.schres.2025.01.002 (Epub ahead of print, PMID: 39864301, Jan 25)
     Schizophr Res. 2025 May 7:S0920-9964(25)00179.
     PubMed    
     
     
     
107. BORNHEIMER LA, Lapidos A, Simmonite M, Suzuki T, et al
     Stress sensitivity, negative affect, and functioning in an early psychosis clinic.
     Schizophr Res. 2025;281:125-131.
     PubMed     Abstract available
     
     
     
108. UPPINKUDRU C, Roy N, Bharath RD, Venkatasubramanian G, et al
     Sustained attenuation of sensorimotor network functional connectivity with acute and maintenance phase risperidone treatment in first-episode schizophrenia.
     Schizophr Res. 2025;281:122-124.
     PubMed    
     
     
     
109. MEINHART A, Schmueser A, Moritz S, Boge K, et al
     Effects of mindfulness- and acceptance-based interventions for individuals with schizophrenia spectrum disorders: A systematic meta-review.
     Schizophr Res. 2025;281:91-107.
     PubMed     Abstract available
     
     
     
110. TATSUMI K, Parfitt A, Weissfeld L, Opler M, et al
     Assessing negative symptoms of schizophrenia in the context of remote independent ratings: a psychometric evaluation of BNSS and PANSS.
     Schizophr Res. 2025;281:108-114.
     PubMed     Abstract available
     
     
     
111. TAMPI RR, Joshi P, Jeste DV
     Psychosis associated with dementia: evaluation and management.
     Schizophr Res. 2025;281:82-90.
     PubMed     Abstract available
     
     
     
112. SHIN J, Wu J, Kim HJ, Xi W, et al
     Neighborhood-level social determinants of suicidality in youth with schizophrenia: An EHR-based study.
     Schizophr Res. 2025;281:74-81.
     PubMed     Abstract available
     
     
     
113. KORALNIK LR, Lafont E, Akerele C, Bonner M, et al
     Mediterranean and standard American diet consumption in psychosis and non-psychosis affective disorders groups: Symptoms and cognition.
     Schizophr Res. 2025;281:60-73.
     PubMed     Abstract available
     
     
     
114. LUCKHOFF HK, Smit AM, Phahladira L, Kilian S, et al
     Childhood trauma associations with changes in body mass index over 12 months of treatment in first-episode schizophrenia spectrum disorders.
     Schizophr Res. 2025;281:52-59.
     PubMed     Abstract available
     
     
     
115. BARTOLOMEO LA, James SH, Berglund AM, Raugh IM, et al
     Digital phenotyping evidence for the reduced positivity offset as a mechanism underlying anhedonia among individuals at clinical high-risk for psychosis.
     Schizophr Res. 2025;281:45-51.
     PubMed     Abstract available
     
     
     April 2025
116. JIA N, Yin X, Zhu Z, Hou W, et al
     Comprehensive transcriptome analysis and lncRNA-miRNA-mRNA establishment of schizophrenia based on induced pluripotent stem cells.
     Schizophr Res. 2025;281:22-29.
     PubMed     Abstract available
     
     
     
117. 
     Commentary on "Speaking of yourself: A meta-analysis of 80 years of research on pronoun use in schizophrenia".
     Schizophr Res. 2025;281:20-21.
     PubMed    
     
     
     
118. RAMIREZ-BERMUDEZ J, Espinola-Nadurille M, Restrepo-Martinez M, Martinez-Angeles V, et al
     Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy.
     Schizophr Res. 2025;281:10-19.
     PubMed     Abstract available
     
     
     
119. TRUJILLO T, Mirzakhanian H, Addington J, Bearden CE, et al
     High rates of suicidality and parasuicidal behavior in individuals at clinical high-risk for psychosis: Implications for suicide risk assessment and suicide prevention.
     Schizophr Res. 2025;281:1-9.
     PubMed     Abstract available
     
     
     
120. SALUJA A, Johnson KA, Ongur D, Lanca M, et al
     Changes in first-episode psychosis care delivery and outcomes throughout the COVID-19 pandemic: Insights from a learning healthcare system in Massachusetts.
     Schizophr Res. 2025;280:130-139.
     PubMed     Abstract available
     
     
     
121. ZHU B, Liang L, Huang Y, Wang H, et al
     Exploring the relationship between the gut microbiota and cognitive function in schizophrenia patients with distinct weights.
     Schizophr Res. 2025;280:103-113.
     PubMed     Abstract available
     
     
     
122. KIDD SA, Rosenbaum D, Rotenberg M, Kenny GP, et al
     Climate change and schizophrenia: Implications and directions.
     Schizophr Res. 2025;280:114-116.
     PubMed    
     
     
     
123. TOUFEILI A, Vigod SN, Zaheer J, Hussain Z, et al
     Reproductive health experiences of women and non-binary people with early psychosis: a qualitative study.
     Schizophr Res. 2025;280:95-102.
     PubMed     Abstract available
     
     
     
124. KNOWLES EEM, Peralta JM, Rodrigue AL, Mathias SR, et al
     Differential gene expression study in whole blood identifies candidate genes for psychosis in African American individuals.
     Schizophr Res. 2025;280:85-94.
     PubMed     Abstract available
     
     
     
125. YANG J, Zhu X, Wang W, Wang H, et al
     Aripiprazole or metformin for hyperprolactinemia in women with schizophrenia: A 6-month, real-world chart review study.
     Schizophr Res. 2025;280:76-84.
     PubMed     Abstract available
     
     
     
126. FOLEY JA, Bell V
     CBT for psychosis in Parkinson's disease: A framework for how and why.
     Schizophr Res. 2025;280:69-75.
     PubMed     Abstract available
     
     
     
127. GUEST RM, Aberizk K, Addington J, Bearden CE, et al
     Cultural variables influence performance on the MATRICS Consensus Cognitive Battery among people at clinical high risk for psychosis.
     Schizophr Res. 2025;280:60-68.
     PubMed     Abstract available
     
     
     
128. CHEN SN, Wang YY
     Reply to dynamic network analysis of schizophrenia spectrum traits, affective symptoms, and social functioning-Opportunities and challenges.
     Schizophr Res. 2025;280:59.
     PubMed    
     
     
     
129. ZHU H, Wu Z, Wang J, Zhang E, et al
     DLG2 rs11607886 polymorphism associated with schizophrenia and precuneus functional changes.
     Schizophr Res. 2025;280:50-58.
     PubMed     Abstract available
     
     
     
130. LU C, Huang D, Su J, Huang Z, et al
     Letter to the editor regarding: Dynamic network analysis of schizophrenia spectrum traits, affective symptoms, and social functioning-Opportunities and challenges.
     Schizophr Res. 2025;280:48-49.
     PubMed    
     
     
     
131. YOO S, Montazeri A, McNulty H, Potvin Kent M, et al
     Global evaluation of the impact of food fortification with folic acid on rates of schizophrenia.
     Schizophr Res. 2025;280:39-47.
     PubMed     Abstract available
     
     
     
132. CHIU CW, Chen BY, Lin JJ, Tseng HH, et al
     Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP(1), EP(2), and EP(4) in the niacin-induced flushing pathway.
     Schizophr Res. 2025;280:30-38.
     PubMed     Abstract available
     
     
     
133. LIU M, Tian S, Liu X, Zhang H, et al
     Analysis of differentially expressed genes in schizophrenia based on bioinformatics and corresponding mRNA expression levels.
     Schizophr Res. 2025;280:22-29.
     PubMed     Abstract available
     
     
     
134. PATEL PK, Thies MB, Moyett A, Arkin S, et al
     Avolition predicts variability in optimal risk-taking in early psychosis.
     Schizophr Res. 2025;280:15-21.
     PubMed     Abstract available
     
     
     
135. FORTIER A, Tikasz A, Athanassiou M, Zouaoui I, et al
     Hippocampus subfield volume reductions in treatment-resistant schizophrenia.
     Schizophr Res. 2025;280:10-14.
     PubMed    
     
     
     
136. MATHIS WS, Gibbs-Dean T, Cahill JD, Srihari VH, et al
     HONE: A learning health system platform for advancing early intervention in first episode psychosis.
     Schizophr Res. 2025;280:1-9.
     PubMed     Abstract available
     
     
     
137. GREVE AN, Hemager N, Piche G, Burton BK, et al
     Perceived social support in parents with schizophrenia or bipolar disorder and their co-parents: The Danish high risk and resilience study VIA 7.
     Schizophr Res. 2025;279:137-143.
     PubMed     Abstract available
     
     
     
138. RETHA S, Hilmar L, Lebogang P, Sanja K, et al
     Corrigendum to "Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months" [Schizophr. Res. volume 276 (2025), 8-14/article number].
     Schizophr Res. 2025 Apr 5:S0920-9964(25)00125.
     PubMed    
     
     
     
139. PALOMINOS C, Kirdun M, Nikzad AH, Spilka MJ, et al
     A single composite index of semantic behavior tracks symptoms of psychosis over time.
     Schizophr Res. 2025;279:116-127.
     PubMed     Abstract available
     
     
     
140. LIU K, Chen HW, Wang SA, Zhang CY, et al
     Association between serum bilirubin and type 2 diabetes mellitus risk: Findings from a schizophrenia cohort.
     Schizophr Res. 2025;279:106-115.
     PubMed     Abstract available
     
     
     
141. CHEN L, Wang Z, Wang Y, Jiang H, et al
     Alterations in fatty acid metabolism in patients with schizophrenia in a multi-omics perspective.
     Schizophr Res. 2025;279:94-105.
     PubMed     Abstract available
     
     
     
142. NIELSEN JRW, Dietz M, Jefsen OH
     Blink rates in patients with schizophrenia compared to healthy controls: A meta-analysis.
     Schizophr Res. 2025;279:87-93.
     PubMed     Abstract available
     
     
     
143. ROBINSON DG, Schooler NR, John M, Cahill JD, et al
     The problem of missing data for learning health systems focused on first-episode psychosis.
     Schizophr Res. 2025;279:79-86.
     PubMed     Abstract available
     
     
     
144. DIOMINO A, Yuan Q, Cadenhead KS, Addington J, et al
     The role of childhood social fragmentation and perceived discrimination on maladaptive core schemas later in life among young adults at clinical high risk for psychosis and healthy comparisons.
     Schizophr Res. 2025;279:71-78.
     PubMed     Abstract available
     
     
     
145. POOLE-WRIGHT K, Patel A, Gaughran F, Murray R, et al
     Prevalence and associations of fatigue in psychosis: A systematic review and meta-analysis.
     Schizophr Res. 2025;279:59-70.
     PubMed     Abstract available
     
     
     
146. BELLO I, Stefancic A, Florence AC, Wall M, et al
     OnTrackNY: A public sector learning healthcare system for youth and young adults with early psychosis.
     Schizophr Res. 2025;279:50-58.
     PubMed     Abstract available
     
     
     
147. YUAN Q, Chen Y, Xu Y, Dimitrov LV, et al
     Cluster profiles of distressing psychotic-like experiences among children and associations with genetic risk, prenatal cannabis exposure, and social-environmental characteristics.
     Schizophr Res. 2025;278:119-127.
     PubMed     Abstract available
     
     
     March 2025
148. LYNE J, Piacenza F, Crowley P, Smyth J, et al
     Negative symptoms in psychosis: A scoping review of qualitative studies.
     Schizophr Res. 2025;279:40-49.
     PubMed     Abstract available
     
     
     
149. PERALTA V, de Jalon EG, Moreno-Izco L, Sanchez-Torres AM, et al
     What does really matter in the premorbid background of psychosis leading to long-term disability? A 21-year follow-up cohort study of first-episode psychosis.
     Schizophr Res. 2025;279:31-39.
     PubMed     Abstract available
     
     
     
150. ELLEUCH D, Chen Y, Luo Q, Palaniyappan L, et al
     Speaking of yourself: A meta-analysis of 80 years of research on pronoun use in schizophrenia.
     Schizophr Res. 2025;279:22-30.
     PubMed     Abstract available
     
     
     
151. PIANI MC, Jandl M, Morishima Y, Nordgaard J, et al
     Self-disorders in schizophrenia - and ERP study of pre-reflective and reflective self-experience.
     Schizophr Res. 2025;279:13-21.
     PubMed     Abstract available
     
     
     
152. PELIZZA L, Leuci E, Quattrone E, Palmisano D, et al
     Compulsory treatment across a 2-year follow-up within an "Early Intervention in Psychosis" program in Italy: Incidence rates and baseline predictors.
     Schizophr Res. 2025;279:1-12.
     PubMed     Abstract available
     
     
     
153. TIAN J, Dong S, Nomura N, Siafis S, et al
     Corrigendum to "Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials" [Schizophr. Res. Volume 274, December 2024, pages 360-373].
     Schizophr Res. 2025 Mar 26:S0920-9964(25)00099.
     PubMed    
     
     
     
154. VOHS JL, Cahill J, Taylor SF, Heckers S, et al
     Forging a learning health system for early psychosis: Insights from the academic community EPINET.
     Schizophr Res. 2025;278:109-118.
     PubMed     Abstract available
     
     
     
155. DENIS D, Baran B, Mylonas D, Spitzer C, et al
     Corrigendum to "Sleep oscillations and their relations with sleep-dependent memory consolidation in early course psychosis and first-degree relatives" [Schizophr. Res. 274 (2024) 473-485].
     Schizophr Res. 2025 Mar 26:S0920-9964(25)00096.
     PubMed    
     
     
     
156. YOVIENE SYKES LA, Levine N, Tayfur SN, Gibbs-Dean T, et al
     The STEP Learning Collaborative: A statewide Learning Healthcare System (LHS) for first episode psychosis.
     Schizophr Res. 2025;278:96-108.
     PubMed     Abstract available
     
     
     
157. DE ALMEIDA QUEIROZ S, de Novais Junior LR, de Carvalho ABP, da Silva TV, et al
     Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model.
     Schizophr Res. 2025;278:82-95.
     PubMed     Abstract available
     
     
     
158. ZHANG S, Jin W, Fan S, Wang Q, et al
     Association of insight with stigma and its moderating factors among patients with stable schizophrenia.
     Schizophr Res. 2025;278:75-81.
     PubMed     Abstract available
     
     
     
159. LOCARNO LR, Lasagna CA, Kraft JD, Suzuki T, et al
     Examining the joint and unique contributions of contour integration and visuospatial memory to altered eye gaze perception in schizophrenia.
     Schizophr Res. 2025;278:65-74.
     PubMed     Abstract available
     
     
     
160. DU L, Huang H, Pu Z, Shi Y, et al
     A potential diagnostic biomarker for schizophrenia based on local functional connectivity using dynamic regional phase synchrony.
     Schizophr Res. 2025;278:57-64.
     PubMed     Abstract available
     
     
     
161. LOURENCO P, Bastos T, Pizarro A, Corredeira R, et al
     The long-term effects of a 24-week outdoor exercise program in persons with schizophrenia: Results of a 12-week follow-up period.
     Schizophr Res. 2025;278:47-56.
     PubMed     Abstract available
     
     
     
162. CRESTOIS N, Kempton MJ, Twumasi R
     A systematic review and meta-analysis of employer discrimination towards people living with psychosis.
     Schizophr Res. 2025;278:35-46.
     PubMed     Abstract available
     
     
     
163. PELUFFO L
     A reflection on schizophrenia's "voices" based on personal experience.
     Schizophr Res. 2025;277:188-189.
     PubMed    
     
     
     
164. KUBOTA R, Uchino T, Okubo R, Akiyama H, et al
     Factor structure of social cognition in schizophrenia: Investigation of four core domains.
     Schizophr Res. 2025;278:26-34.
     PubMed     Abstract available
     
     
     
165. ALVIM PHP, Cavalari VC, Bianchini AJ, Frizon GF, et al
     Toxoplasmosis infection and schizophrenia: Elevated IgM reactivity index as a predictor of symptom worsening in chronic schizophrenia.
     Schizophr Res. 2025;278:20-25.
     PubMed     Abstract available
     
     
     
166. WANG S, Dong Y, Qiu Y, Sun X, et al
     Prediction of treatment response in drug-naive schizophrenia patients from the perspective of targeted metabolomics.
     Schizophr Res. 2025;278:9-16.
     PubMed     Abstract available
     
     
     
167. HUANG HC, Wu BJ, Yu CH, Liu CZ, et al
     LEPR gene polymorphisms and pneumonia risk in Taiwanese schizophrenia patients under clozapine treatment.
     Schizophr Res. 2025;278:1-8.
     PubMed     Abstract available
     
     
     
168. EVANS SL, Kumari V, Kempton MJ, Rogers J, et al
     MRI data sharing in psychosis: Key challenges and a new Open Access resource for researchers.
     Schizophr Res. 2025;277:185-187.
     PubMed    
     
     
     
169. LIU Z, Wang X, Chen W, Huang J, et al
     Comparison of clinical symptoms and symptom structure across different onset ages in schizophrenia inpatients.
     Schizophr Res. 2025;277:177-184.
     PubMed     Abstract available
     
     
     
170. JIANG C, Wang J, Sun Y, Tan S, et al
     Unveiling distinct representations of P3a in schizophrenia through two-stimulus and three-stimulus auditory oddball paradigms.
     Schizophr Res. 2025;277:159-168.
     PubMed     Abstract available
     
     
     
171. ABERIZK K, Sefik E, Yuan Q, Cao H, et al
     Relations of temporoparietal connectivity with neighborhood social fragmentation in youth at clinical high-risk for psychosis.
     Schizophr Res. 2025;277:151-158.
     PubMed     Abstract available
     
     
     
172. ETIENNE M, Verdoux H
     Impact of long-acting injectable antipsychotics in early psychosis: An umbrella review.
     Schizophr Res. 2025;277:140-150.
     PubMed     Abstract available
     
     
     
173. ZHANG L, Zhang C, Yan H, Han Y, et al
     Changes in degree centrality and its associated genes: A longitudinal study of patients with schizophrenia undergoing pharmacological treatment.
     Schizophr Res. 2025;277:130-139.
     PubMed     Abstract available
     
     
     
174. DOW JF, Cerundolo N, Konstas K, Carol EE, et al
     Implementing early psychosis services: Experiences from the laboratory for early psychosis center.
     Schizophr Res. 2025;277:124-129.
     PubMed     Abstract available
     
     
     
175. QIN X, Wang Q, Li H, Wang J, et al
     Effects of tDCS with concurrent cognitive performance targeting the dorsolateral prefrontal cortex and the posterior parietal cortex on EEG microstates in schizophrenia.
     Schizophr Res. 2025;277:117-123.
     PubMed     Abstract available
     
     
     
176. CHENG B, Wen Y, Wei W, Cheng S, et al
     Polygenic enrichment analysis in multi-omics levels identifies cell/tissue specific associations with schizophrenia based on single-cell RNA sequencing data.
     Schizophr Res. 2025;277:93-101.
     PubMed     Abstract available
     
     
     
177. LEUTWYLER H, Mock J, Hubbard E, Bussell T, et al
     Social and environmental factors during the smoking cessation process: The experiences of adults with serious mental illnesses.
     Schizophr Res. 2025;277:111-116.
     PubMed     Abstract available
     
     
     February 2025
178. MARSTELLER JA, Goldberg RW, Boumaiz Y, Jumper MBE, et al
     Building a two-state learning healthcare system for persons with first episode psychosis.
     Schizophr Res. 2025;277:74-85.
     PubMed     Abstract available
     
     
     
179. VON KANEL S, Pavlidou A, Nadesalingam N, Chapellier V, et al
     Manual dexterity and grip force are distinctly linked to domains of neurological soft signs in schizophrenia spectrum disorders.
     Schizophr Res. 2025;277:65-73.
     PubMed     Abstract available
     
     
     
180. KAISER KA, Thompson JL, Butler PD, Ahmed AO, et al
     Effects of visual remediation on Ebbinghaus illusion task performance in people with schizophrenia: A preliminary study.
     Schizophr Res. 2025;277:57-64.
     PubMed     Abstract available
     
     
     
181. KAMP D, Lowe A, Weide K, Riesbeck M, et al
     Efficacy of integrated social cognitive remediation vs neurocognitive remediation in schizophrenia: Results from the multicenter randomized controlled ISST (Integrated Social Cognition And Social Skills Therapy) study.
     Schizophr Res. 2025;277:44-56.
     PubMed     Abstract available
     
     
     
182. VERAS AB, Ribeiro KM, Peixoto C, Horato N, et al
     Schizophrenia spectrum disorders with comorbid panic: A systematic review.
     Schizophr Res. 2025;277:33-41.
     PubMed     Abstract available
     
     
     
183. TAKEUCHI H
     Are all antipsychotic dose reduction trials in stable schizophrenia the same?
     Schizophr Res. 2025;277:31-32.
     PubMed    
     
     
     
184. ABDEL-BAKI A, Ferrari M, Leblanc A, Arbaud C, et al
     SARPEP, a rapid-learning healthcare system of early intervention services for psychosis in Quebec, Canada: Feasibility, acceptability and early impacts.
     Schizophr Res. 2025;277:20-30.
     PubMed     Abstract available
     
     
     
185. SUN X, Xu Y, Wu Y, Li M, et al
     Sex differences in the relationship between the vascular endothelial growth factor and cognition in drug-naive schizophrenia.
     Schizophr Res. 2025;277:9-17.
     PubMed     Abstract available
     
     
     
186. ORTH RD, Todd IL, Dwyer KR, Bennett ME, et al
     Socially relevant affective learning in psychosis: Relations to deficits in motivation and pleasure and cognitive ability.
     Schizophr Res. 2025;277:1-8.
     PubMed     Abstract available
     
     
     
187. FAGGIANO A, Gherbesi E, Carugo S, Grassi G, et al
     Myocardial mechanics in schizophrenia and bipolar disorder: A gap to fill.
     Schizophr Res. 2025;276:243-249.
     PubMed     Abstract available
     
     
     
188. HAGEN JM, Cornelissen A, Veeneman RR, van der Heijden HS, et al
     Skin advanced glycation end products, indicating cumulative oxidative stress, associated with schizophrenia but not with psychosis-like experiences.
     Schizophr Res. 2025;276:237-242.
     PubMed     Abstract available
     
     
     
189. JIAO X, Hu Q, Zhu W, Ren W, et al
     A letter to the editor: Abnormalities in auditory lateralization during spatial mismatch negativity tasks in male patients with schizophrenia.
     Schizophr Res. 2025;276:234-236.
     PubMed    
     
     
     
190. HAN S, Gilmartin M, Sheng W, Jin VX, et al
     Integrating rare variant genetics and brain transcriptome data implicates novel schizophrenia putative risk genes.
     Schizophr Res. 2025;276:205-213.
     PubMed     Abstract available
     
     
     
191. HECHINGER RM, Javaras KN, Lewandowski KE
     Comorbidity of anorexia nervosa and schizophrenia: A systematic review.
     Schizophr Res. 2025;276:185-193.
     PubMed     Abstract available
     
     
     
192. AGUIRRE JM, Diaz Dellarossa C, Barbagelata D, Vasquez J, et al
     Cognitive function at first episode in patients subsequently developing treatment-resistant schizophrenia.
     Schizophr Res. 2025;276:178-184.
     PubMed     Abstract available
     
     
     
193. LIU L, Xia Y, Chen L, Zou F, et al
     Binaural hearing impairment in patients with schizophrenia: A multicenter study.
     Schizophr Res. 2025;276:175-177.
     PubMed    
     
     
     
194. ALARCON-YAQUETTO DE, Stewart R, Perera G, Pinto da Costa M, et al
     Impact of loneliness and living alone on negative symptoms in severe mental illness: An electronic health record data analysis.
     Schizophr Res. 2025;276:196-201.
     PubMed     Abstract available
     
     
     January 2025
195. KEMP KC, Tso IF, Taylor SF, Moe AM, et al
     Social stress in schizophrenia: Unique contributions to social cognition and social functioning.
     Schizophr Res. 2025;276:167-174.
     PubMed     Abstract available
     
     
     
196. ERESHEFSKY S, Gemignani R, Savill M, Sanford KC, et al
     A mixed-methods study exploring the benefits, drawbacks, and utilization of data in care: Findings from the EPI-CAL early psychosis learning health care network.
     Schizophr Res. 2025;276:157-166.
     PubMed     Abstract available
     
     
     
197. SHARMA D, Bharadaj SK, Bharadaj S, Chakraborty S, et al
     MicroRNA-regulated suppression of some overexpressed genes in schizophrenia and their evolutionary significance.
     Schizophr Res. 2025;276:143-156.
     PubMed     Abstract available
     
     
     
198. DELAY C, Link P, Holden J, Granholm E, et al
     Using pupillometry to predict outcome in cognitive behavioral therapy for negative symptoms of schizophrenia.
     Schizophr Res. 2025;276:135-142.
     PubMed     Abstract available
     
     
     
199. DE WITH J, van der Pluijm M, de Haan L, Schirmbeck F, et al
     The role of the behavioural inhibition and activation system in the association between attachment style and positive or negative symptoms in patients with psychosis and unaffected siblings.
     Schizophr Res. 2025;276:127-134.
     PubMed     Abstract available
     
     
     
200. HARVEY PD, Kaul I, Chataverdi S, Patel T, et al
     Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia.
     Schizophr Res. 2025;276:117-126.
     PubMed     Abstract available
     
     
     
201. CHAKRABORTY A, Mukesh N, Annamneedi A
     Synaptic dysfunctions in schizophrenia: Commonalities and divergences in Chinese and Indian populations.
     Schizophr Res. 2025;276:106-107.
     PubMed    
     
     
     
202. JANG YJ, Yassin W, Mesholam-Gately R, Gershon ES, et al
     Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics.
     Schizophr Res. 2025;276:88-96.
     PubMed     Abstract available
     
     
     
203. MA Y, Bai L, Jiang Y, Wang J, et al
     Ambient coarse particulate matter pollution and hospital admissions for schizophrenia.
     Schizophr Res. 2025;276:79-87.
     PubMed     Abstract available
     
     
     
204. GLEESON JFM, Ludwig K, Stiles BJ, Piantella S, et al
     Systematic review and meta-analysis of family-based interventions for early psychosis: Carer and patient outcomes.
     Schizophr Res. 2025;276:57-78.
     PubMed     Abstract available
     
     
     
205. NOGUEIRA C, Pereira ED, Coelho JCF, Moreno-Poyato AR, et al
     Positive mental health interventions for people with schizophrenia: A scoping review.
     Schizophr Res. 2025;276:40-56.
     PubMed     Abstract available
     
     
     
206. FRITZE S, Brandt GA, Volkmer S, Daub J, et al
     Loneliness is associated with different structural brain changes in schizophrenia spectrum disorders and major depression.
     Schizophr Res. 2025;276:31-39.
     PubMed     Abstract available
     
     
     
207. JELSMA A, Schirmbeck F, van der Pluijm M, Simons C, et al
     Obsessive-compulsive symptoms and personal recovery in patients with schizophrenia spectrum disorders: A cross-sectional study.
     Schizophr Res. 2025;276:24-30.
     PubMed     Abstract available
     
     
     
208. BLACKMAN G, DeLaney J, MacCabe JH, Khandaker G, et al
     Sub-clinical systemic inflammation as a determinant of admission duration in psychosis.
     Schizophr Res. 2025;276:17-23.
     PubMed     Abstract available
     
     
     
209. ELKIS H, Correll CU, Melzer-Ribeiro DL
     Response to the Letter to the Editor "Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia" (Jolly et al. Schizophrenia Research, 267 (2024) 32-33).
     Schizophr Res. 2025;276:15-16.
     PubMed    
     
     
     
210. RETHA S, Hilmar L, Lebogang P, Sanja K, et al
     Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months.
     Schizophr Res. 2025;276:8-14.
     PubMed     Abstract available
     
     
     
211. LOPEZ MA, Reznik SJ, Klodnick VV, Cohen D, et al
     Creating a collaborative culture of learning within a network of community mental health early psychosis programs in Texas.
     Schizophr Res. 2025;276:1-7.
     PubMed     Abstract available
     
     
     
212. KOPELOVICH SL, Straub K, Vaswani-Bye A, Brian RM, et al
     Co-production of a state-funded centralized psychosis and psychosis risk screening, assessment, and referral service.
     Schizophr Res. 2025;275:196-207.
     PubMed     Abstract available
     
     
     
213. TAYFUR SN, Song Z, Li F, Hazan H, et al
     Insight and suicidality in first-episode psychosis: The mediating role of depression.
     Schizophr Res. 2025;275:189-195.
     PubMed     Abstract available
     
     
     December 2024
214. SANAHAN R, Sreeraj VS, Suhas S, Kumar V, et al
     Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: A retrospective chart review.
     Schizophr Res. 2024;275:179-188.
     PubMed     Abstract available
     
     
     
215. RUSSELL MT, Linton IS, Vohs JL, Minor KS, et al
     Optimizing recovery in first-episode psychosis: A systematic review of psychosocial interventions.
     Schizophr Res. 2024;275:166-178.
     PubMed     Abstract available
     
     
     
216. BROBAKKEN MF, Nygard M, Guzey IC, Morken G, et al
     The long-lasting impact of high-intensity training via collaborative care in patients with schizophrenia: A 5-year follow-up study.
     Schizophr Res. 2024;275:156-165.
     PubMed     Abstract available
     
     
     
217. KIM EY, Kim J, Jeong JH, Jang J, et al
     Machine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics.
     Schizophr Res. 2024;275:146-155.
     PubMed     Abstract available
     
     
     
218. KIMHY D, Vakhrusheva J, Zemon V
     Affective predictors of social support in individuals with schizophrenia.
     Schizophr Res. 2024;275:137-145.
     PubMed     Abstract available
     
     
     
219. WADA A, Yamada R, Yamada Y, Sumiyoshi C, et al
     Autistic trait severity in early schizophrenia: Role in subjective quality of life and social functioning.
     Schizophr Res. 2024;275:131-136.
     PubMed     Abstract available
     
     
     
220. POUGET JG, Cohen E, Ray JG, Wilton AS, et al
     Association between maternal schizophrenia and risk of serious asthma exacerbations in childhood.
     Schizophr Res. 2024;275:123-130.
     PubMed     Abstract available
     
     
     
221. LI J, Pang L, Liu F, Lu Z, et al
     Disentangling the topological symptom structure of schizophrenia: A network analysis.
     Schizophr Res. 2024;275:115-122.
     PubMed     Abstract available
     
     
     
222. ISHIZUKA M, Otsuka S, Miyata J, Yoshihara Y, et al
     Autism-spectrum quotient mediates the relationship between clinical symptoms and quality of life in schizophrenia.
     Schizophr Res. 2024;275:98-106.
     PubMed     Abstract available
     
     
     
223. DAVIES K, Lappin JM, Briggs N, Isobel S, et al
     Does shame mediate the influence of trauma on psychosis? A systematic review and meta-analytic structural equation modelling approach.
     Schizophr Res. 2024;275:87-97.
     PubMed     Abstract available
     
     
     
224. BRUNNER G, Gajwani R, Gross J, Gumley A, et al
     Choroid plexus morphology in schizophrenia and early-stage psychosis: A cross-sectional study.
     Schizophr Res. 2024;275:107-114.
     PubMed     Abstract available
     
     
     
225. JEFFREY C, Penney D, Sauve G, Mendelson D, et al
     Does metacognitive training for psychosis (MCT) improve neurocognitive performance? A systematic review and meta-analysis.
     Schizophr Res. 2024;275:79-86.
     PubMed     Abstract available
     
     
     
226. COLIJN MA
     16p11.2 duplication syndrome-associated psychosis: An illustrative case and review of the literature.
     Schizophr Res. 2024;275:76-78.
     PubMed    
     
     
     
227. ZURLO L, Dal Bo E, Gentili C, Cecchetto C, et al
     Olfactory dysfunction in schizophrenia and other psychotic disorders: A comprehensive and updated meta-analysis.
     Schizophr Res. 2024;275:62-75.
     PubMed     Abstract available
     
     
     
228. KIDD SA, D'Arcey J, Tackaberry-Giddens L, Asuncion TR, et al
     App for independence: A feasibility randomized controlled trial of a digital health tool for schizophrenia spectrum disorders.
     Schizophr Res. 2024;275:52-61.
     PubMed     Abstract available
     
     
     
229. ZHU Z, Roy D, Feng S, Vogler B, et al
     AI-based medication adherence prediction in patients with schizophrenia and attenuated psychotic disorders.
     Schizophr Res. 2024;275:42-51.
     PubMed     Abstract available
     
     
     
230. ODUOLA S, D'Andrea G, Smimmo D, Menchetti M, et al
     Pathways to care: Source of referral at first-episode psychosis, a cross-country comparison between Bologna and South London.
     Schizophr Res. 2024;275:35-41.
     PubMed     Abstract available
     
     
     
231. DAZZI F, Shafer A
     Meta-analysis of the factor structure of the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS).
     Schizophr Res. 2024;274:464-472.
     PubMed     Abstract available
     
     
     
232. BABADI B, Dokholyan K, DeTore NR, Tootell RBH, et al
     Arousal responses to personal space intrusions in psychotic illness: A virtual reality study.
     Schizophr Res. 2024;274:158-170.
     PubMed     Abstract available
     
     
     November 2024
233. SAGER REH, North HF, Weissleder C, Clearwater MS, et al
     Divergent changes in complement pathway gene expression in schizophrenia and bipolar disorder: Links to inflammation and neurogenesis in the subependymal zone.
     Schizophr Res. 2024;275:25-34.
     PubMed     Abstract available
     
     
     
234. CHONG YY, Chien WT, Mou H, Ip CK, et al
     Acceptance and Commitment Therapy-based Lifestyle Counselling Program for people with early psychosis on physical activity: A pilot randomized controlled trial.
     Schizophr Res. 2024;275:1-13.
     PubMed     Abstract available
     
     
     
235. LAPPAS AS, Ioannou M, Christodoulou NG
     Histopathological evidence of cellular alterations in the dentate gyrus is associated with aberrant RB1CC1-ATG16L1 expression in the hippocampus among older adults with chronic schizophrenia: A pilot post-mortem study.
     Schizophr Res. 2024;275:14-24.
     PubMed     Abstract available
     
     
     
236. HARDY A, Taylor KM, Grant A, Christie L, et al
     Co-designing technology to improve psychological therapy for psychosis: SloMo, a blended digital therapy for fear of harm from others.
     Schizophr Res. 2024;274:526-534.
     PubMed     Abstract available
     
     
     
237. LI J, He J, Ren H, Li Z, et al
     Free-water imaging in subcortical gray matter in schizophrenia patients with persistent auditory verbal hallucinations.
     Schizophr Res. 2024;274:517-525.
     PubMed     Abstract available
     
     
     
238. KESHAVAN MS, Seif P, Tandon R
     Muscarinic deficits - part of a cholinergic-dopaminergic- glutamatergic imbalance in schizophrenia?
     Schizophr Res. 2024;274:508-510.
     PubMed    
     
     
     
239. CAI H, Shen B, Long JX, Huang XL, et al
     Network analysis of psychotic symptoms in schizophrenia.
     Schizophr Res. 2024;274:501-507.
     PubMed     Abstract available
     
     
     
240. POKORNY VJ, Sponheim SR, Olman CA
     Orientation-dependent contextual modulation of contrast in schizophrenia.
     Schizophr Res. 2024;274:492-500.
     PubMed     Abstract available
     
     
     
241. JIMENEZ AM, Green MF
     Self-disturbance in schizophrenia: Updating the research and bridging the gaps.
     Schizophr Res. 2024;274:489-491.
     PubMed    
     
     
     
242. DENIS D, Baran B, Mylonas D, Spitzer C, et al
     Sleep oscillations and their relations with sleep-dependent memory consolidation in early course psychosis and first-degree relatives.
     Schizophr Res. 2024;274:473-485.
     PubMed     Abstract available
     
     
     
243. SUN X, Li M, Qiu Y, Su Q, et al
     Plasma NGAL, not IFN-gamma, predicts early treatment response in drug-naive Chinese Han schizophrenia patients.
     Schizophr Res. 2024;274:457-463.
     PubMed     Abstract available
     
     
     
244. LUCKHOFF HK, Del Re EC, Smit R, Kilian S, et al
     Sex versus gender associations with depressive symptom trajectories over 24 months in first-episode schizophrenia spectrum disorders.
     Schizophr Res. 2024;274:450-456.
     PubMed     Abstract available
     
     
     
245. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
     Validation of the Amharic version of Cognitive Assessment Interview (CAI-A) in people with schizophrenia in Ethiopia.
     Schizophr Res. 2024;274:441-449.
     PubMed     Abstract available
     
     
     
246. XU L, Yang W, Fan R, Wu Y, et al
     A novel digital intervention for improving cognitive impairment in patients with chronic schizophrenia: A randomized clinical trial.
     Schizophr Res. 2024;274:433-440.
     PubMed     Abstract available
     
     
     
247. YAEGASHI H, Haga M, Misawa F, Mizuno Y, et al
     Intentional non-adherence to antipsychotic medication in patients with schizophrenia.
     Schizophr Res. 2024;274:427-432.
     PubMed     Abstract available
     
     
     
248. NI P, Ma Y, Chung S
     Mitochondrial dysfunction in psychiatric disorders.
     Schizophr Res. 2024;273:62-77.
     PubMed     Abstract available
     
     
     October 2024
249. ALI MP, Tiles-Sar N, Simons CJP, Osicka DA, et al
     Does stigma leave its mark? The interplay between negative effects of perceived stigma with positive effect of self-esteem on long-term social functioning in schizophrenia.
     Schizophr Res. 2024;274:417-426.
     PubMed     Abstract available
     
     
     
250. ANDERSON JC, Seitz DP, Crockford D, Addington D, et al
     Quality indicators for schizophrenia care: A scoping review.
     Schizophr Res. 2024;274:406-416.
     PubMed     Abstract available
     
     
     
251. BERGSON Z, Ahmed AO, Bell J, Butler PD, et al
     Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial.
     Schizophr Res. 2024;274:396-405.
     PubMed     Abstract available
     
     
     
252. REZAEI K, Sanchez-Rico M, Garces-Gonzalez MS, Vandel P, et al
     Mortality among older people with late-onset and non-late-onset schizophrenia: A 5-year prospective multicenter study.
     Schizophr Res. 2024;274:393-395.
     PubMed    
     
     
     
253. JUCKEL G
     Reply to Dyadic interaction in schizophrenia - A promising new avenue of investigation?
     Schizophr Res. 2024;274:392.
     PubMed    
     
     
     
254. ABDULLAHI A, Wong TW, Ng SS
     Understanding the potential mechanisms of disease modifying effects of physical activity and exercise in people with schizophrenia.
     Schizophr Res. 2024;274:381-391.
     PubMed     Abstract available
     
     
     
255. TIAN J, Dong S, Nomura N, Siafis S, et al
     Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
     Schizophr Res. 2024;274:360-373.
     PubMed     Abstract available
     
     
     
256. LI S, Lu C, Liu N, Li Y, et al
     Association between auditory P300 event-related potential and suicidal thoughts and behaviors in first-episode antipsychotic-naive patients with schizophrenia.
     Schizophr Res. 2024;274:352-359.
     PubMed     Abstract available
     
     
     
257. GENG C, Chen C
     Bidirectional Mendelian randomization to explore the causal relationships between schizophrenia and narcolepsy.
     Schizophr Res. 2024;274:345-351.
     PubMed     Abstract available
     
     
     
258. ISMAIL Z, Meehan SR, Farovik A, Miguelez M, et al
     Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale.
     Schizophr Res. 2024;274:337-344.
     PubMed     Abstract available
     
     
     
259. DEWAN M, Campbell Daniels E, Hunt JE, Bryant EA, et al
     Aberrant salience signaling in auditory processing in schizophrenia: Evidence for abnormalities in both sensory processing and emotional reactivity.
     Schizophr Res. 2024;274:329-336.
     PubMed     Abstract available
     
     
     
260. SABBAH SG, Northoff G
     Basic self-disturbance in schizophrenia: From neuronal to mental topographic dedifferentiation.
     Schizophr Res. 2024;274:327-328.
     PubMed    
     
     
     
261. ULIANA DL, Martinez A, Grace AA
     THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.
     Schizophr Res. 2024;274:315-326.
     PubMed     Abstract available
     
     
     
262. DE BEER F, Wijnen B, Wouda L, Koops S, et al
     Antipsychotic dopamine D(2) affinity and negative symptoms in remitted first episode psychosis patients.
     Schizophr Res. 2024;274:299-306.
     PubMed     Abstract available
     
     
     
263. ZHOU Y, Zheng Q, Tian J
     Letter to the editor regarding "The effects of mindful exercise on cognition in patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials".
     Schizophr Res. 2024;274:288-289.
     PubMed    
     
     
     
264. JAMBAWO SM, Owolewa R, Jambawo TT
     The effectiveness of peer support on the recovery and empowerment of people with schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2024;274:270-279.
     PubMed     Abstract available
     
     
     
265. FOERSTER FR, Joos E, Martin B, Coull JT, et al
     Corrigendum to "Self and time in individuals with schizophrenia: A motor component?" [Schizophr. Res. 272 (2024) 12-19 (October)].
     Schizophr Res. 2024;274:269.
     PubMed    
     
     
     
266. CHENG W, Zhao M, Zhang X, Zhou X, et al
     Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis.
     Schizophr Res. 2024;274:257-268.
     PubMed     Abstract available
     
     
     
267. SARANGI S, Sharma S, Nahak SK, Panda AK, et al
     Association of CACNA1C polymorphisms (rs1006737, rs4765905, rs2007044) with schizophrenia: A meta-analysis and trial sequential analysis.
     Schizophr Res. 2024;274:247-256.
     PubMed     Abstract available
     
     
     
268. COWAN HR
     Aligning phenomenology and neuroscience of the basic and narrative self in schizophrenia.
     Schizophr Res. 2024;274:245-246.
     PubMed    
     
     
     
269. HAJDUK M, Park S, Pinkham AE
     Dyadic interaction in schizophrenia - A promising new avenue of investigation?
     Schizophr Res. 2024;274:243-244.
     PubMed    
     
     
     
270. BRANDT AS, Nucifora FC Jr, Zandi PP, Margolis RL, et al
     The timing and severity of clozapine-associated neutropenia in the US: Is the risk overstated?
     Schizophr Res. 2024;272:104-109.
     PubMed     Abstract available
     
     
     
271. BJORNESTAD J, Tjora T, Joa I, Johannessen JO, et al
     Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis.
     Schizophr Res. 2024;274:237-242.
     PubMed     Abstract available
     
     
     September 2024
272. JOHNSTONE S, Hubbard AN, Schenkel A, Ashare RL, et al
     Effects of acute smoking abstinence among people with schizophrenia: A systematic review and meta-analysis of laboratory studies.
     Schizophr Res. 2024;274:220-236.
     PubMed     Abstract available
     
     
     
273. WRIGHT AC, McKenna A, Tice JA, Rind DM, et al
     A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia.
     Schizophr Res. 2024;274:212-219.
     PubMed     Abstract available
     
     
     
274. RESTELLINI R, Golay P, Jenni R, Baumann PS, et al
     Winter birth: A factor of poor functional outcome in a Swiss early psychosis cohort.
     Schizophr Res. 2024;274:206-211.
     PubMed     Abstract available
     
     
     
275. WANG X, Wang RX, Bian C, Liu FY, et al
     Sleep quality, psychological resilience, family resilience, social support, and mental disability in patients with chronic schizophrenia: A cross-sectional study.
     Schizophr Res. 2024;274:199-205.
     PubMed     Abstract available
     
     
     
276. POLETTI M, Raballo A
     Schizophrenia spectrum disorders in children and adolescents: Clinical, phenomenological, diagnostic, and prognostic features across subtypes.
     Schizophr Res. 2024;274:189-198.
     PubMed     Abstract available
     
     
     
277. LEE HS, Sangimino M, Baxter T, Buck L, et al
     Self-other boundary under social threat in schizophrenia.
     Schizophr Res. 2024;274:182-188.
     PubMed     Abstract available
     
     
     
278. LUCKHOFF H, Smit R, Del Re E, Kilian S, et al
     Associations of sexual orientation with symptom profiles in first-episode schizophrenia spectrum disorders.
     Schizophr Res. 2024;274:180-181.
     PubMed    
     
     
     
279. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
     Corrigendum to "Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers" [Schizophr. Res. 266 (2024) 183-189].
     Schizophr Res. 2024;274:178-179.
     PubMed    
     
     
     
280. ZILBERSTEIN T, Shomron B
     The depiction of people with schizophrenia in news media: A cross-national analysis.
     Schizophr Res. 2024;274:171-177.
     PubMed     Abstract available
     
     
     
281. PHALEN P, Jones N, Davis B, Sarpal D, et al
     Suicidality among clients in a network of coordinated specialty care (CSC) programs for first-episode psychosis: Rates, changes in rates, and their predictors.
     Schizophr Res. 2024;274:150-157.
     PubMed     Abstract available
     
     
     
282. PELIZZA L, Leuci E, Quattrone E, Azzali S, et al
     Rates and predictors of service disengagement in first episode psychosis: Results from a 2-year follow-up study in an Italian real-world care setting.
     Schizophr Res. 2024;274:142-149.
     PubMed     Abstract available
     
     
     
283. MOLHO W, Stiltner B, Raymond N, Kiely C, et al
     Retinal electrophysiological alterations are associated with cognition in early course psychosis.
     Schizophr Res. 2024;274:137-141.
     PubMed     Abstract available
     
     
     
284. SNELLEKSZ M, Scarr E, Dean B
     Lower levels of kainate receptors, but not AMPA or NMDA receptors, in Brodmann's area (BA) 9, but not BA 10, from a subgroup of people with schizophrenia who have a marked deficit in cortical muscarinic M1 receptors.
     Schizophr Res. 2024;274:129-136.
     PubMed     Abstract available
     
     
     
285. KIZILAY E, Arslan B, Verim B, Demirlek C, et al
     Automated linguistic analysis in youth at clinical high risk for psychosis.
     Schizophr Res. 2024;274:121-128.
     PubMed     Abstract available
     
     
     
286. SU Q, Xuekelaiti Z, Ma H, Qiu Y, et al
     The associations between duration of untreated psychosis, growth factors, and neurocognition in patients with drug-naive schizophrenia.
     Schizophr Res. 2024;274:113-120.
     PubMed     Abstract available
     
     
     
287. SHAKIR M, van Harten PN, Hoogendoorn AW, Willems AE, et al
     Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects.
     Schizophr Res. 2024;274:105-112.
     PubMed     Abstract available
     
     
     
288. GARTNER SP, Olesen TB, Jensen H, Mortensen LM, et al
     Recognition of schizophrenia and quality of treatment during the COVID-19 pandemic: A Danish nationwide study.
     Schizophr Res. 2024;274:98-104.
     PubMed     Abstract available
     
     
     
289. WU C, She S, Gong B, Li Q, et al
     Spontaneous neural activity underlying neutral and happy speech recognition in noise and its association with psychiatric symptoms in patients with schizophrenia.
     Schizophr Res. 2024;274:90-97.
     PubMed     Abstract available
     
     
     
290. SALVI V, Tripodi B, Cerveri G, Migliarese G, et al
     Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.
     Schizophr Res. 2024;274:78-89.
     PubMed     Abstract available
     
     
     
291. LEE R, Griffiths SL, Gkoutos GV, Wood SJ, et al
     Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model.
     Schizophr Res. 2024;274:66-77.
     PubMed     Abstract available
     
     
     
292. HORAN WP, Targum SD, Claxton A, Kaul I, et al
     Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
     Schizophr Res. 2024;274:57-65.
     PubMed     Abstract available
     
     
     
293. RAJ V, Stogios N, Agarwal SM, Cheng AJ, et al
     The neuromuscular basis of functional impairment in schizophrenia: A scoping review.
     Schizophr Res. 2024;274:46-56.
     PubMed     Abstract available
     
     
     
294. KRAMER M, Fink F, Campo LA, Akinci E, et al
     Video analysis of interaction in schizophrenia reveals functionally relevant abnormalities.
     Schizophr Res. 2024;274:24-32.
     PubMed     Abstract available
     
     
     
295. THOMPSON JL, Silverstein SM, Papathomas TV, Keane BP, et al
     Hallucinations and the depth-inversion illusion in schizophrenia.
     Schizophr Res. 2024;274:21-23.
     PubMed    
     
     
     
296. STARZER M, Hansen HG, Hjorthoj C, Albert N, et al
     Long-term quality of life and social disconnection 20 years after a first episode psychosis, results from the 20-year follow-up of the OPUS trial.
     Schizophr Res. 2024;274:33-45.
     PubMed     Abstract available
     
     
     
297. ALESSANDRO DL, Leuci E, Quattrone E, Azzali S, et al
     Obsessive-compulsive symptoms in individuals at clinical high risk for psychosis: A 2-year longitudinal study.
     Schizophr Res. 2024;274:11-20.
     PubMed     Abstract available
     
     
     
298. GREENWAY FT, Weal M, Palmer-Cooper EC
     Hybrid mHealth care: Patient perspectives of blended treatments for psychosis. A systematic review.
     Schizophr Res. 2024;274:1-10.
     PubMed     Abstract available
     
     
     
299. SMUCNY J, Wood A, Davidson IN, Carter CS, et al
     Are factors that predict conversion to psychosis associated with initial transition to a high risk state? An adolescent brain cognitive development study analysis.
     Schizophr Res. 2024;272:128-132.
     PubMed     Abstract available
     
     
     
300. TERENZI D, Silvetti M, Zoccolan G, Rumiati RI, et al
     The impact of subclinical psychotic symptoms on delay and effort discounting: Insights from behavioral, computational, and electrophysiological methods.
     Schizophr Res. 2024;271:271-280.
     PubMed     Abstract available
     
     
     
301. HARVEY PD, Davidson M, Saoud JB, Kuchibhatla R, et al
     Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria.
     Schizophr Res. 2024;271:246-252.
     PubMed     Abstract available
     
     
     
302. GONZALO-DE MIGUEL A, Abascal-Peiro S, Cegla-Schvartzman FB, Martinez-Ales G, et al
     Antipsychotic use in a large community sample of patients with delusional disorder.
     Schizophr Res. 2024;271:194-199.
     PubMed     Abstract available
     
     
     
303. SARPAL DK
     Astrocytic contributions to clozapine response: Potential support for a psychopharmacologic glial process.
     Schizophr Res. 2024;271:142-143.
     PubMed    
     
     
     
304. ARORA S, Suhas S, Gowda GS, Reddi VSK, et al
     DRESS syndrome, seizures, and myocarditis on low dose clozapine - A case report.
     Schizophr Res. 2024;271:391-393.
     PubMed    
     
     
     August 2024
305. REAVIS EA, Wynn JK, Green MF
     Pre-stimulus EEG phase coherence predicts visual target detection failures in schizophrenia: A pilot study.
     Schizophr Res. 2024;272:112-119.
     PubMed     Abstract available
     
     
     
306. ELKIS H, Melzer-Ribeiro DL, Napolitano IC
     Response to Markota et al. "Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia" SCHRES-D-24-00481.
     Schizophr Res. 2024;272:110-111.
     PubMed    
     
     
     
307. LIZANO P, Karmacharya R
     Harnessing stem cell-based approaches for clinically meaningful discoveries in schizophrenia.
     Schizophr Res. 2024 Aug 29:S0920-9964(24)00377.
     PubMed    
     
     
     
308. SONG SH, Hayirli TC, Shore O, Coconcea C, et al
     Atypical presentation of schizophrenia with ablution avoidance: A case report.
     Schizophr Res. 2024;272:96-97.
     PubMed    
     
     
     
309. MLAKAR V, Akkouh I, Halff EF, Srivastava DP, et al
     Telomere biology and its maintenance in schizophrenia spectrum disorders: Exploring links to cognition.
     Schizophr Res. 2024;272:89-95.
     PubMed     Abstract available
     
     
     
310. COTTER SJ, Smith CL, Gao CX, Khanna R, et al
     What impact did the COVID-19 pandemic have on psychosis and the delivery of early intervention psychosis services?
     Schizophr Res. 2024;272:79-88.
     PubMed     Abstract available
     
     
     
311. MARKOTA M, Croarkin PE, Coombes BJ, Gentry MT, et al
     Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia.
     Schizophr Res. 2024;272:77-78.
     PubMed    
     
     
     
312. SHIRINBAKHSHMASOLEH M, Aboulatta L, Leong C, Riel H, et al
     The impact of COVID-19 public health measures on the utilization of antipsychotics in schizophrenia in Manitoba - A population-based study.
     Schizophr Res. 2024;272:69-76.
     PubMed     Abstract available
     
     
     
313. TARGUM SD, Ge T, Asgharnejad M, Reksoprodjo P, et al
     Use of video-recordings of site-based interviews for quality assurance in a study of subjects with schizophrenia and persistent negative symptoms.
     Schizophr Res. 2024;272:61-68.
     PubMed     Abstract available
     
     
     
314. JIMENEZ AM, Green MF
     Disturbance at the self-other boundary in schizophrenia: Linking phenomenology to clinical neuroscience.
     Schizophr Res. 2024;272:51-60.
     PubMed     Abstract available
     
     
     
315. LIU Z, Sun YH, Ren Y, Perez JM, et al
     Upregulated solute-carrier family genes in the hippocampus of schizophrenia can be rescued by antipsychotic medications.
     Schizophr Res. 2024;272:39-50.
     PubMed     Abstract available
     
     
     
316. REDLICH BOSSY M, Muller DR, Jabat M, Burrer A, et al
     Relationship between psychopathological symptoms and dimensions in inpatients with schizophrenia: A network analysis.
     Schizophr Res. 2024;272:36-38.
     PubMed    
     
     
     
317. POLETTI M, Raballo A
     Ontogenesis of self-disorders in the schizophrenia spectrum: A phenomenological neuro-developmental model.
     Schizophr Res. 2024;272:26-35.
     PubMed     Abstract available
     
     
     
318. GU B, Rose J, Kurtz MM
     Cognitive training for schizophrenia: Do race and ethnicity matter?
     Schizophr Res. 2024;272:20-25.
     PubMed     Abstract available
     
     
     
319. FOERSTER FR, Joos E, Martin B, Coull JT, et al
     Self and time in individuals with schizophrenia: A motor component?
     Schizophr Res. 2024;272:12-19.
     PubMed     Abstract available
     
     
     
320. LOCHMANN VAN BENNEKOM MWH, IntHout J, Gijsman HJ, Akdede BBK, et al
     Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data.
     Schizophr Res. 2024;272:1-11.
     PubMed     Abstract available
     
     
     
321. MESSINIS A, Panteli E, Paraskevopoulou A, Zymarikopoulou AK, et al
     Altered lipidomics biosignatures in schizophrenia: A systematic review.
     Schizophr Res. 2024;271:380-390.
     PubMed     Abstract available
     
     
     
322. HE Q, Zhu P, Liu X, Huo C, et al
     Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis.
     Schizophr Res. 2024;271:371-379.
     PubMed     Abstract available
     
     
     
323. PIRAS M, Popovic I, Ranjbar S, Grosu C, et al
     Aripiprazole dose associations with metabolic adverse effect: Results from a longitudinal study.
     Schizophr Res. 2024;270:403-409.
     PubMed     Abstract available
     
     
     
324. KOHLER-FORSBERG O, Hojlund M, Rohde C, Kemp AF, et al
     Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials.
     Schizophr Res. 2024;270:135-143.
     PubMed     Abstract available
     
     
     July 2024
325. VAN DYNE A, Wu TC, Adamowicz DH, Lee EE, et al
     Longitudinal relationships between BMI and hs-CRP among people with schizophrenia.
     Schizophr Res. 2024;271:337-344.
     PubMed     Abstract available
     
     
     
326. PROKOPEZ CR, Cesarini JI, Corral RM, Sere L, et al
     Renaming schizophrenia in Argentina: Could a change of name resolve the stigma? Results from a national survey.
     Schizophr Res. 2024;271:334-336.
     PubMed    
     
     
     
327. EACK SM
     Defeatist beliefs about performance are important treatment targets for negative symptoms in the early course of schizophrenia.
     Schizophr Res. 2024;271:332-333.
     PubMed    
     
     
     
328. KENNEDY L, Ku BS, Addington J, Amir CM, et al
     Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts.
     Schizophr Res. 2024;271:319-331.
     PubMed     Abstract available
     
     
     
329. CHEN CC, Howie J, Ebrahimi M, Teymouri K, et al
     Analysis of the complement component C4 gene with schizophrenia subphenotypes.
     Schizophr Res. 2024;271:309-318.
     PubMed     Abstract available
     
     
     
330. SALVADE A, Golay P, Abrahamyan L, Bonnarel V, et al
     Gender differences in first episode psychosis: Some arguments to develop gender specific treatment strategies.
     Schizophr Res. 2024;271:300-308.
     PubMed     Abstract available
     
     
     
331. WANG Y, Ouyang L, Fan L, Zheng W, et al
     Functional and structural abnormalities of thalamus in individuals at early stage of schizophrenia.
     Schizophr Res. 2024;271:292-299.
     PubMed     Abstract available
     
     
     
332. SICOTTE R, D'Andrea G, Dumais A, Crocker AG, et al
     Aggressive behaviors in first-episode psychosis: Distinction between the premorbid phase and the onset of psychosis.
     Schizophr Res. 2024;271:283-291.
     PubMed     Abstract available
     
     
     
333. MILLGATE E, Smart SE, Pardinas AF, Kravariti E, et al
     Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181].
     Schizophr Res. 2024;270:495-496.
     PubMed    
     
     
     
334. ASAI T, Ikegame T, Satomura Y, Kumagai E, et al
     Lower plasma betaine levels in men at clinical high risk for psychosis: Findings from a metabolomics investigation.
     Schizophr Res. 2024;271:281-282.
     PubMed    
     
     
     
335. STEPHENS RL, Leavitt I, Cornea E, Jarskog LF, et al
     Early cognitive development and psychopathology in children at familial high risk for schizophrenia.
     Schizophr Res. 2024;271:262-270.
     PubMed     Abstract available
     
     
     
336. ABEL DB, Vohs JL, Salyers MP, Wu W, et al
     Social anhedonia in the daily lives of people with schizophrenia: Examination of anticipated and consummatory pleasure.
     Schizophr Res. 2024;271:253-261.
     PubMed     Abstract available
     
     
     
337. CHEN CR, Lee YW, Chen TT, Hsu CW, et al
     The effects of mindful exercise on cognition in patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
     Schizophr Res. 2024;271:237-245.
     PubMed     Abstract available
     
     
     
338. CORADDUZZA D, di Lorenzo B, Sedda S, Nivoli AM, et al
     Investigating bilirubin concentrations in schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2024;271:228-236.
     PubMed     Abstract available
     
     
     
339. SOLEIMANI MF, Ayubi E, Khosronezhad S, Hasler G, et al
     Human endogenous retroviruses type W (HERV-) activation and schizophrenia: A meta-analysis.
     Schizophr Res. 2024;271:220-227.
     PubMed     Abstract available
     
     
     
340. COSTA DFB, Rossignoli P, Pontarolli DRS, Junior PC, et al
     Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in Brazil.
     Schizophr Res. 2024;271:200-205.
     PubMed     Abstract available
     
     
     
341. KADIVAR A, Ilapakurti M, Dobkins K, Cadenhead KS, et al
     Visual contrast sensitivity in clinical high risk and first episode psychosis.
     Schizophr Res. 2024;271:186-193.
     PubMed     Abstract available
     
     
     
342. WINKLER K, Lincoln TM, Wiesjahn M, Jung E, et al
     How does loneliness interact with positive, negative and depressive symptoms of psychosis? New insights from a longitudinal therapy process study.
     Schizophr Res. 2024;271:179-185.
     PubMed     Abstract available
     
     
     
343. RYCHAGOV N, Del Re EC, Zeng V, Oykhman E, et al
     Gyrification across psychotic disorders: A bipolar-schizophrenia network of intermediate phenotypes study.
     Schizophr Res. 2024;271:169-178.
     PubMed     Abstract available
     
     
     
344. KENNEDY KP, Zito MF, Marder SR
     Does relapse cause illness progression in first-episode psychosis? A review.
     Schizophr Res. 2024;271:161-168.
     PubMed     Abstract available
     
     
     
345. CHINTOH A, Liu L, Braun A, Akseer S, et al
     Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis.
     Schizophr Res. 2024;271:153-160.
     PubMed     Abstract available
     
     
     
346. KOSTER M, van der Pluijm M, van de Giessen E, Schrantee A, et al
     The association of tobacco smoking and metabolite levels in the anterior cingulate cortex of first-episode psychosis patients: A case-control and 6-month follow-up (1)H-MRS study.
     Schizophr Res. 2024;271:144-152.
     PubMed     Abstract available
     
     
     
347. AL-CHALABI N, Nader G, Fischer C, Graff A, et al
     Effect of DNA methylation and AUDIT-C polygenic scores on alcohol use disorder comorbidity in psychoses: No evidence of epigenetic basis of polygenic risk.
     Schizophr Res. 2024;271:138-141.
     PubMed    
     
     
     
348. CARRION RE, Ku BS, Dorvil S, Auther AM, et al
     Neurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning.
     Schizophr Res. 2024;271:129-137.
     PubMed     Abstract available
     
     
     
349. LI R, Cao M, Fu D, Wei W, et al
     Deciphering language disturbances in schizophrenia: A study using fine-tuned language models.
     Schizophr Res. 2024;271:120-128.
     PubMed     Abstract available
     
     
     
350. FEOLA B, Flook EA, Seo DJ, Fox V, et al
     Altered brain and physiological stress responses in early psychosis.
     Schizophr Res. 2024;271:112-119.
     PubMed     Abstract available
     
     
     
351. KREIS I, Lagerberg TV, Wold KF, Asbo G, et al
     Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use.
     Schizophr Res. 2024;271:91-99.
     PubMed     Abstract available
     
     
     
352. LISBOA JRF, Costa O, Pakes GH, Colodete DAE, et al
     Perineuronal net density in schizophrenia: A systematic review of postmortem brain studies.
     Schizophr Res. 2024;271:100-109.
     PubMed     Abstract available
     
     
     
353. LAK M, Jafarpour A, Shahrbaf MA, Lak M, et al
     The effect of physical exercise on cognitive function in schizophrenia patients: A GRADE assessed systematic review and meta-analysis of controlled clinical trials.
     Schizophr Res. 2024;271:81-90.
     PubMed     Abstract available
     
     
     
354. MACHIRAJU SN, Wyss J, Light G, Braff DL, et al
     Novel N100 area reliably captures aberrant sensory processing and is associated with neurocognition in early psychosis.
     Schizophr Res. 2024;271:71-80.
     PubMed     Abstract available
     
     
     
355. BIONDI M, Marino M, Mantini D, Spironelli C, et al
     Unveiling altered connectivity between cognitive networks and cerebellum in schizophrenia.
     Schizophr Res. 2024;271:47-58.
     PubMed     Abstract available
     
     
     
356. VARATHAN A, Senthooran S, Jeyananthan P
     Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study.
     Schizophr Res. 2024;271:38-46.
     PubMed     Abstract available
     
     
     
357. DROSOS P, Johnsen E, Bartz-Johannessen CA, Larsen TK, et al
     Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
     Schizophr Res. 2024;271:9-18.
     PubMed     Abstract available
     
     
     
358. LATRECHE I, Slatnia S, Kazar O, Harous S, et al
     Identification and diagnosis of schizophrenia based on multichannel EEG and CNN deep learning model.
     Schizophr Res. 2024;271:28-35.
     PubMed     Abstract available
     
     
     
359. DWYER GE, Johnsen E, Hugdahl K
     NMDAR dysfunction and the regulation of dopaminergic transmission in schizophrenia.
     Schizophr Res. 2024;271:19-27.
     PubMed     Abstract available
     
     
     
360. CORBERA S, Wexler BE, Bell MD, Pittman B, et al
     Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder.
     Schizophr Res. 2024;271:1-8.
     PubMed     Abstract available
     
     
     
361. ZAMPERONI G, Tan EJ, Sumner PJ, Rossell SL, et al
     Exploring the conceptualisation, measurement, clinical utility and treatment of formal thought disorder in psychosis: A Delphi study.
     Schizophr Res. 2024;270:486-493.
     PubMed     Abstract available
     
     
     
362. LIU L, Ren D, Li K, Ji L, et al
     Unraveling schizophrenia's genetic complexity through advanced causal inference and chromatin 3D conformation.
     Schizophr Res. 2024;270:476-485.
     PubMed     Abstract available
     
     
     
363. BARNBY JM, Haslbeck JMB, Rosen C, Sharma R, et al
     Modelling the longitudinal dynamics of paranoia in psychosis: A temporal network analysis over 20 years.
     Schizophr Res. 2024;270:465-475.
     PubMed     Abstract available
     
     
     
364. LUI SSY, Lam EHY, Wang LL, Leung PBM, et al
     Negative symptoms in treatment-resistant schizophrenia and its relationship with functioning.
     Schizophr Res. 2024;270:459-464.
     PubMed     Abstract available
     
     
     
365. THIBAULT M, Romain AJ, Tessier C, Theagene JMJ, et al
     Feasibility and Acceptability of a Physical Activity Group Program Using telerehabilitation during the COVID-19 Pandemic in Multiple early Intervention for Psychosis Services.
     Schizophr Res. 2024;270:451-458.
     PubMed     Abstract available
     
     
     
366. WOLD KF, Ottesen A, Flaaten CB, Kreis I, et al
     Childhood trauma and treatment resistance in first-episode psychosis: Investigating the role of premorbid adjustment and duration of untreated psychosis.
     Schizophr Res. 2024;270:441-450.
     PubMed     Abstract available
     
     
     
367. MIHURA JL, Boyette LL, Gorner KJ, Kleiger JH, et al
     Improving dependability in science: A critique on the psychometric qualities of the HiTOP psychosis superspectrum.
     Schizophr Res. 2024;270:433-440.
     PubMed     Abstract available
     
     
     
368. LIN D, Fu Z, Liu J, Perrone-Bizzozero N, et al
     Association between the oral microbiome and brain resting state connectivity in schizophrenia.
     Schizophr Res. 2024;270:392-402.
     PubMed     Abstract available
     
     
     
369. GALUBA V, Cordes J, Feyerabend S, Riesbeck M, et al
     Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
     Schizophr Res. 2024;270:383-391.
     PubMed     Abstract available
     
     
     
370. MORRIS A, Reed T, McBride G, Chen J, et al
     Dietary interventions to improve metabolic health in schizophrenia: A systematic literature review of systematic reviews.
     Schizophr Res. 2024;270:372-382.
     PubMed     Abstract available
     
     
     
371. MORFINI F, Bauer CCC, Zhang J, Whitfield-Gabrieli S, et al
     Targeting the superior temporal gyrus with real-time fMRI neurofeedback: A pilot study of the indirect effects on self-referential processes in schizophrenia.
     Schizophr Res. 2024;270:358-365.
     PubMed     Abstract available
     
     
     
372. DING Y, Hou W, Wang C, Sha S, et al
     Longitudinal changes in cognitive function in early psychosis: a meta-analysis with the MATRICS consensus cognitive battery (MCCB).
     Schizophr Res. 2024;270:349-357.
     PubMed     Abstract available
     
     
     
373. HEUSCHEN CBBCM, Bolhuis K, Zantvoord JB, Bockting CL, et al
     Self-reported suicidal ideation among individuals with first episode psychosis and healthy controls: Findings from the international multicentre EU-GEI study.
     Schizophr Res. 2024;270:339-348.
     PubMed     Abstract available
     
     
     
374. LIU Y, Wu H, Liu B, Chen S, et al
     Multi-omics analysis reveals the impact of gut microbiota on antipsychotic-induced weight gain in schizophrenia.
     Schizophr Res. 2024;270:325-338.
     PubMed     Abstract available
     
     
     
375. LIN PY, Chen YH, Chang YJ, Chen JW, et al
     Deep learning for schizophrenia classification based on natural language processing-A pilot study.
     Schizophr Res. 2024;270:323-324.
     PubMed    
     
     
     
376. CORRIPIO I, Fraguas D, Garcia-Portilla MP, Olivares JM, et al
     Functioning in schizophrenia: Recommendations of an expert panel.
     Schizophr Res. 2024;270:317-322.
     PubMed     Abstract available
     
     
     
377. MANA L, Schwartz-Palleja M, Vila-Vidal M, Deco G, et al
     Overview on cognitive impairment in psychotic disorders: From impaired microcircuits to dysconnectivity.
     Schizophr Res. 2024;269:132-143.
     PubMed     Abstract available
     
     
     
378. ELKIS H, Melzer-Ribeiro DL, Napolitano IC, Correll CU, et al
     The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES- role of ECT in patients with CRS-Markota et al. 2024.
     Schizophr Res. 2024;269:120-122.
     PubMed    
     
     
     June 2024
379. JEONG JH, Kim SW, Yu JC, Won SH, et al
     Clinical, cognitive, and functional characteristics of recent-onset psychosis with autistic features: A 2-year longitudinal study.
     Schizophr Res. 2024;270:304-316.
     PubMed     Abstract available
     
     
     
380. SOURANDER A, Upadhyaya S, Surcel HM, Hinkka-Yli-Salomaki S, et al
     Maternal vitamin D levels during pregnancy and offspring schizophrenia.
     Schizophr Res. 2024;270:289-294.
     PubMed     Abstract available
     
     
     
381. HU W, Ran X, Wu Z, Zhu H, et al
     Short-term antipsychotic treatment reduces functional connectivity of the striatum in first-episode drug-naive early-onset schizophrenia.
     Schizophr Res. 2024;270:281-288.
     PubMed     Abstract available
     
     
     
382. HAMERS IMH, Brand BA, Begemann MJH, Weickert CS, et al
     The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.
     Schizophr Res. 2024;270:273-280.
     PubMed     Abstract available
     
     
     
383. IGLESIAS-MARTINEZ-ALMEIDA M, Campos-Rios A, Freiria-Martinez L, Rivera-Baltanas T, et al
     Characterization and modulation of voltage-gated potassium channels in human lymphocytes in schizophrenia.
     Schizophr Res. 2024;270:260-272.
     PubMed     Abstract available
     
     
     
384. KURTULMUS A, Yildiz FBP
     The potential role of gamma-secretase complex in schizophrenia: Bridging neurodevelopmental and neurodegenerative hypotheses.
     Schizophr Res. 2024;270:258-259.
     PubMed    
     
     
     
385. MURTHY V, Hanson E, DeMartinis N, Asgharnejad M, et al
     INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia.
     Schizophr Res. 2024;270:249-257.
     PubMed     Abstract available
     
     
     
386. JACOBSEN SL, Kohler-Forsberg O, Rohde C
     Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
     Schizophr Res. 2024;270:231-234.
     PubMed    
     
     
     
387. NOGUEIRA GN, Andrade AGM, Guimaraes APC, Gomes SP, et al
     Exploring substance use in first episode psychoses, what can we do more?
     Schizophr Res. 2024;270:229-230.
     PubMed    
     
     
     
388. SKIBA RM, Chinchani AM, Menon M, Lepage M, et al
     Overlap between individual differences in cognition and symptoms of schizophrenia.
     Schizophr Res. 2024;270:220-228.
     PubMed     Abstract available
     
     
     
389. FILIP TF, Hellemann GS, Ventura J, Subotnik KL, et al
     Defeatist performance beliefs in individuals with recent-onset schizophrenia: Relationships with cognition and negative symptoms.
     Schizophr Res. 2024;270:212-219.
     PubMed     Abstract available
     
     
     
390. HE H, Long J, Song X, Li Q, et al
     A connectome-wide association study of altered functional connectivity in schizophrenia based on resting-state fMRI.
     Schizophr Res. 2024;270:202-211.
     PubMed     Abstract available
     
     
     
391. PARNAS J, Sandsten KE
     The phenomenological nature of schizophrenia and disorder of selfhood.
     Schizophr Res. 2024;270:197-201.
     PubMed     Abstract available
     
     
     
392. TAN EJ, Rossell SL
     Exploring associations between trait symptoms and speech patterns in schizophrenia spectrum disorders: A mediation analysis.
     Schizophr Res. 2024;270:188-190.
     PubMed    
     
     
     
393. WANG C, Zhang Y, Chong JS, Zhang W, et al
     Altered functional connectivity subserving expressed emotion environments in schizophrenia: An fNIRS study.
     Schizophr Res. 2024;270:178-187.
     PubMed     Abstract available
     
     
     
394. MOHN C, Ueland T, Haatveit B, Saether LS, et al
     Neurocognitive function and delusion severity in schizophrenia spectrum disorders.
     Schizophr Res. 2024;270:172-177.
     PubMed     Abstract available
     
     
     
395. ZHANG R, Lei X, Ren J, Zhang C, et al
     The roles of extracellular vesicle-derived microRNAs in schizophrenia: A scoping review.
     Schizophr Res. 2024;270:162-164.
     PubMed    
     
     
     
396. TORRES-CARMONA E, Nakajima S, Iwata Y, Ueno F, et al
     Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.
     Schizophr Res. 2024;270:152-161.
     PubMed     Abstract available
     
     
     
397. BROBAKKEN MF, Nygard M, Vedul-Kjelsas E, Harvey PD, et al
     Everyday function in schizophrenia: The impact of aerobic endurance and skeletal muscle strength.
     Schizophr Res. 2024;270:144-151.
     PubMed     Abstract available
     
     
     
398. DUNMON D, Schooler NR, Severe JB, Buckley PF, et al
     Insomnia and cardiovascular disease risk in schizophrenia.
     Schizophr Res. 2024;270:132-134.
     PubMed    
     
     
     
399. NASRALLAH HA
     Is self-disturbance in schizophrenia due to inter- and intra-hemispheric white matter dysconnectivity?
     Schizophr Res. 2024;270:129-131.
     PubMed    
     
     
     
400. SAKAKIBARA E, Satomura Y, Matsuoka J, Koike S, et al
     Abnormal resting-state hyperconnectivity in schizophrenia: A whole-head near-infrared spectroscopy study.
     Schizophr Res. 2024;270:121-128.
     PubMed     Abstract available
     
     
     
401. NIBBIO G, Pinton IC, Barlati S, Stanga V, et al
     Predictors of psychosocial functioning in people diagnosed with schizophrenia spectrum disorders that committed violent offences and in those that did not: Results of the Recoviwel study.
     Schizophr Res. 2024;270:112-120.
     PubMed     Abstract available
     
     
     
402. CHEN X, Huang H, Pu Z, Shi Y, et al
     Increased risk of atypical antipsychotics-induced metabolic syndrome associated with MIF CATT >5/6 among females with chronic schizophrenia.
     Schizophr Res. 2024;270:94-101.
     PubMed     Abstract available
     
     
     
403. PANY S, Rawat K, Swami MK
     Sleep patterns in treated and untreated patients of schizophrenia.
     Schizophr Res. 2024;270:111.
     PubMed    
     
     
     
404. SHEINBAUM T, Gizdic A, Kwapil TR, Barrantes-Vidal N, et al
     A longitudinal study of the impact of childhood adversity dimensions on social and psychological factors and symptoms of psychosis, depression, and anxiety.
     Schizophr Res. 2024;270:102-110.
     PubMed     Abstract available
     
     
     
405. SHEN C, Tong X, Ran J, Sun S, et al
     Associations between residential environments and late-onset schizophrenia in UK Biobank: Interaction with genetic risk factor.
     Schizophr Res. 2024;270:85-93.
     PubMed     Abstract available
     
     
     
406. MOROSAN L, de Almeida ER, van der Tuin S, van den Berg D, et al
     The impact of daily social support on the associations between daily negative events and daily suspiciousness across different clinical stages of psychosis.
     Schizophr Res. 2024;270:76-84.
     PubMed    
     
     
     
407. DEFAYETTE AB, Silverstein SM, Pisani AR
     Social network structure as a biopsychosocial suicide prevention target for young people at clinical high-risk for psychosis.
     Schizophr Res. 2024;270:63-67.
     PubMed     Abstract available
     
     
     
408. SANDSTEN KE, Jensen MT, Saebye D, Null K, et al
     Altered cardiac autonomic functioning associates with self-disorders in schizophrenia.
     Schizophr Res. 2024;270:57-62.
     PubMed     Abstract available
     
     
     
409. CECERSKA-HERYC E, Polikowska A, Serwin N, Michalczyk A, et al
     The importance of oxidative biomarkers in diagnosis, treatment, and monitoring schizophrenia patients.
     Schizophr Res. 2024;270:44-56.
     PubMed     Abstract available
     
     
     
410. MUKAI Y, Lupinacci R, Marder S, Snow-Adami L, et al
     Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial.
     Schizophr Res. 2024;270:37-43.
     PubMed     Abstract available
     
     
     
411. ABDOLIZADEH A, Hosseini Kupaei M, Kambari Y, Amaev A, et al
     The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2024;270:11-36.
     PubMed     Abstract available
     
     
     
412. DE LEON J
     Promoting safer and wider worldwide use of clozapine.
     Schizophr Res. 2024;268:1-6.
     PubMed     Abstract available
     
     
     
413. NIITSU T, Yasui-Furukori N, Inada K, Kanazawa T, et al
     Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey.
     Schizophr Res. 2024;268:82-87.
     PubMed     Abstract available
     
     
     
414. BAPTISTA T, Motuca M, Serrano A, Perez Lo Presti A, et al
     An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance.
     Schizophr Res. 2024;268:60-65.
     PubMed     Abstract available
     
     
     
415. KUZO N, Blyzniuk B, Chumakov E, Seifritz E, et al
     Clozapine research standards in former USSR states: A systematic review of quality issues with recommendations for future harmonization with modern research standards.
     Schizophr Res. 2024;268:48-52.
     PubMed     Abstract available
     
     
     
416. MEYER JM
     Making sense of norclozapine levels: 3 clinical axioms.
     Schizophr Res. 2024;268:289-292.
     PubMed     Abstract available
     
     
     
417. VERDOUX H, Quiles C, de Leon J
     Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations.
     Schizophr Res. 2024;268:243-251.
     PubMed     Abstract available
     
     
     
418. ZOLEZZI M, Eltorki Y
     A brief history and challenges of clozapine utilization in the Arab world.
     Schizophr Res. 2024;268:21-24.
     PubMed    
     
     
     
419. YANG Z, Takeuchi H, Yee JY, See YM, et al
     Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore.
     Schizophr Res. 2024;268:66-73.
     PubMed     Abstract available
     
     
     
420. MUNOZ-MANCHADO LI, Perez-Revuelta JI, Banerjee A, Galindo-Guarin L, et al
     Influence of time to clozapine prescription on the clinical outcome.
     Schizophr Res. 2024;268:189-192.
     PubMed     Abstract available
     
     
     
421. SAGUD M, Breznoscakova D, Celofiga A, Chihai J, et al
     An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance.
     Schizophr Res. 2024;268:53-59.
     PubMed     Abstract available
     
     
     
422. SANKARANARAYANAN A, Kazi S, Andrade C
     Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia.
     Schizophr Res. 2024;268:145-149.
     PubMed     Abstract available
     
     
     
423. SCHULTE PFJ, Veerman SRT, Bakker B, Bogers JPAM, et al
     Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
     Schizophr Res. 2024;268:74-81.
     PubMed     Abstract available
     
     
     
424. KIRILOCHEV O, Chumakov E, Kuzo N, Schoretsanitis G, et al
     A scoping review of literature on clozapine from former USSR states published in Russian language.
     Schizophr Res. 2024;268:38-47.
     PubMed     Abstract available
     
     
     
425. CARSWELL O, Wilton LR, Nicholls K, Thomas V, et al
     A 12-month audit of clozapine associated myocarditis in a South Australian Local Health Network: The importance of screening and personalised titration.
     Schizophr Res. 2024;268:88-93.
     PubMed     Abstract available
     
     
     
426. DE LEON J, Wang L, Simpson GM
     The introduction of clozapine at the Nathan Kline Institute in New York and its long-term consequences.
     Schizophr Res. 2024;268:14-20.
     PubMed     Abstract available
     
     
     
427. LEUNG JG, Allen ND, Markota M
     A case series of clozapine titrations affected by inflammatory processes.
     Schizophr Res. 2024;268:94-97.
     PubMed    
     
     
     
428. KELLY DL, Glassman M, Wonodi I, Vyas G, et al
     Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial.
     Schizophr Res. 2024;268:312-322.
     PubMed     Abstract available
     
     
     
429. CLARK SR, Wilton LR, Dawson JL, Chiew K, et al
     Dotting the I's and crossing the T's: A South Australian perspective on variability in troponin thresholds for myocarditis risk in clozapine treatment.
     Schizophr Res. 2024;268:114-117.
     PubMed    
     
     
     
430. RUAN CJ, Olmos I, Ricciardi C, Schoretsanitis G, et al
     Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies.
     Schizophr Res. 2024;268:293-301.
     PubMed     Abstract available
     
     
     
431. LIN SK, Lane HY
     A brief history of clozapine use in Taiwan.
     Schizophr Res. 2024;268:34-37.
     PubMed     Abstract available
     
     
     
432. GROVER S, Naskar C
     Patient and caregivers perspective about clozapine: A systematic review.
     Schizophr Res. 2024;268:223-232.
     PubMed     Abstract available
     
     
     
433. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
     Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: A retrospective chart review of seven hospitals.
     Schizophr Res. 2024;268:98-106.
     PubMed     Abstract available
     
     
     
434. SCHORETSANITIS G, Anil Yagcioglu AE, Ruan CJ, Eap CB, et al
     Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition.
     Schizophr Res. 2024;268:302-307.
     PubMed     Abstract available
     
     
     
435. RUAN CJ, Wang CY, Zang YN, Liu CG, et al
     A brief history of clozapine in China with a look forward.
     Schizophr Res. 2024;268:25-28.
     PubMed     Abstract available
     
     
     
436. VERDOUX H, Quiles C, de Leon J
     Risks and benefits of clozapine and lithium co-prescribing: A systematic review and expert recommendations.
     Schizophr Res. 2024;268:233-242.
     PubMed     Abstract available
     
     
     May 2024
437. BARRUEL D, Hilbey J, Charlet J, Chaumette B, et al
     Predicting treatment resistance in schizophrenia patients: Machine learning highlights the role of early pathophysiologic features.
     Schizophr Res. 2024;270:1-10.
     PubMed     Abstract available
     
     
     
438. SABBAH SG, Northoff G
     Global neural self-disturbance in schizophrenia: A systematic fMRI review.
     Schizophr Res. 2024;269:163-173.
     PubMed     Abstract available
     
     
     
439. GALLESE V, Ardizzi M, Ferroni F
     Schizophrenia and the bodily self.
     Schizophr Res. 2024;269:152-162.
     PubMed     Abstract available
     
     
     
440. VARAMBALLY S, Holla B, Venkatasubramanian G, Mullapudi T, et al
     Clinical effects of a yoga-based intervention for patients with schizophrenia - A six-month randomized controlled trial.
     Schizophr Res. 2024;269:144-151.
     PubMed     Abstract available
     
     
     
441. MARKOTA M, Croarkin PE, Gentry MT, Leung JG, et al
     Role of electroconvulsive therapy in patients with clozapine-refractory schizophrenia.
     Schizophr Res. 2024;269:130-131.
     PubMed    
     
     
     
442. REN H, Li J, Zhou J, Chen X, et al
     Grey matter volume reduction in the frontotemporal cortex associated with persistent verbal auditory hallucinations in Chinese patients with chronic schizophrenia: Insights from a 3 T magnetic resonance imaging study.
     Schizophr Res. 2024;269:123-129.
     PubMed     Abstract available
     
     
     
443. GABBERT T, Scheunemann J, Balzan RP, Doehring N, et al
     The contributions of risk-taking and impulsivity to jumping to conclusions in the psychosis spectrum.
     Schizophr Res. 2024;269:116-119.
     PubMed     Abstract available
     
     
     
444. VILLA J, Campbell DG, Parrish EM, Jeon ME, et al
     Associations between fearlessness about death and suicidal ideation in individuals with psychosis.
     Schizophr Res. 2024;269:96-102.
     PubMed     Abstract available
     
     
     
445. ADELINO MPM, Nunes MV, Nunes MFQ, Quarantini LC, et al
     Efficacy of sodium nitroprusside in the treatment of drug-naive subjects in first episode psychosis - An open label study.
     Schizophr Res. 2024;269:114-115.
     PubMed    
     
     
     
446. TORRES-CARMONA E, Ueno F, Iwata Y, Nakajima S, et al
     Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure.
     Schizophr Res. 2024;269:103-113.
     PubMed     Abstract available
     
     
     
447. BOSE A, Agarwal SM, Nawani H, Shivakumar V, et al
     Effect of add-on tDCS therapy for auditory hallucinations on frequency and duration deviant mismatch negativity in schizophrenia.
     Schizophr Res. 2024;269:93-95.
     PubMed    
     
     
     
448. AVERSA S, Ghanem J, Grunfeld G, Lemonde AC, et al
     Sociodemographic and clinical correlates of hallucinations in patients entering an early intervention program for first episode psychosis.
     Schizophr Res. 2024;269:86-92.
     PubMed     Abstract available
     
     
     
449. ALLIENDE LM, Strauss GP, Yang LH, Mittal VA, et al
     Perceptions of stigma in youth at clinical high risk for psychosis and depressive symptomatology.
     Schizophr Res. 2024;269:79-85.
     PubMed     Abstract available
     
     
     
450. KIM E, Redwood S, Liu F, Roche DJO, et al
     Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia.
     Schizophr Res. 2024;269:71-78.
     PubMed     Abstract available
     
     
     
451. CHIAPPELLI J, Savransky A, Ma Y, Gao S, et al
     Impact of lifetime stressor exposure on neuroenergetics in schizophrenia spectrum disorders.
     Schizophr Res. 2024;269:58-63.
     PubMed     Abstract available
     
     
     
452. JOSE BJ, Antonio GA, Reveca GF
     Cortisol response in individuals with genetic risk of schizophrenia. Some considerations.
     Schizophr Res. 2024;269:56-57.
     PubMed    
     
     
     
453. FENG S, Huang Y, Li H, Zhou S, et al
     Dynamic effective connectivity in the cerebellar dorsal dentate nucleus and the cerebrum, cognitive impairment, and clinical correlates in patients with schizophrenia.
     Schizophr Res. 2024 May 9:S0920-9964(24)00184.
     PubMed     Abstract available
     
     
     
454. ZHU Q, Jiang G, Zheng Y, Fu Z, et al
     The effect of cognitive impairment based on Mini-Mental State Examination (MMSE) on suicidal tendency in patients with schizophrenia: A large cross-sectional study.
     Schizophr Res. 2024;269:48-55.
     PubMed     Abstract available
     
     
     
455. LI N, Li Y, Yu T, Gou M, et al
     Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia.
     Schizophr Res. 2024;269:36-47.
     PubMed     Abstract available
     
     
     
456. WANG Y, Xu Y, Wu P, Zhou Y, et al
     Exploring the interplay between core and mood symptoms in schizophrenia: A network analysis.
     Schizophr Res. 2024;269:28-35.
     PubMed     Abstract available
     
     
     
457. SHIMADA T, Morimoto T, Nagayama H, Nakamura N, et al
     Effect of individualized occupational therapy on cognition among patients with schizophrenia: A randomized controlled trial.
     Schizophr Res. 2024;269:18-27.
     PubMed     Abstract available
     
     
     
458. ZHANG C, Liang J, Yan H, Li X, et al
     Fractional amplitude of low-frequency fluctuations in sensory-motor networks and limbic system as a potential predictor of treatment response in patients with schizophrenia.
     Schizophr Res. 2024 May 3:S0920-9964(24)00173.
     PubMed     Abstract available
     
     
     
459. DAUB J, Brandt GA, Volkmer S, Northoff G, et al
     Arthur Schopenhauer: An underappreciated philosopher in psychiatry and his applied epistemology of body and self- experience.
     Schizophr Res. 2024;267:487-496.
     PubMed     Abstract available
     
     
     
460. LYNE J, Piacenza F, Radovic J, O'Donoghue B, et al
     The effectiveness of adjunctive cariprazine for treatment of negative symptoms: A systematic review of randomised controlled trials.
     Schizophr Res. 2024;267:213-215.
     PubMed    
     
     
     
461. TIRUPATI S, Arachchi MK
     Reply to "Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter Region of Australia".
     Schizophr Res. 2024;267:191-192.
     PubMed    
     
     
     
462. VAN DER HEIDE DH, Bogers JPAM, Schulte PRFJ
     Recovery from leukopenia after discontinuation of clozapine does not exclude lymphoma.
     Schizophr Res. 2024;267:72-74.
     PubMed    
     
     
     
463. KIKUCHI Y, Komatsu H, Tomita H
     Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia.
     Schizophr Res. 2024;267:42-43.
     PubMed    
     
     
     April 2024
464. SASS L, Feyaerts J
     Schizophrenia, the very idea: On self-disorder, hyperreflexivity, and the diagnostic concept.
     Schizophr Res. 2024 Apr 30:S0920-9964(24)00122.
     PubMed     Abstract available
     
     
     
465. ALBEELY AM, Williams OOF, Blight CR, Theriault RK, et al
     Sex differences in neuronal oscillatory activity and memory in the methylazoxymethanol acetate model of schizophrenia.
     Schizophr Res. 2024;267:451-461.
     PubMed     Abstract available
     
     
     
466. LI H, Huang Y, Liang L, Li H, et al
     The relationship between the gut microbiota and oxidative stress in the cognitive function of schizophrenia: A pilot study in China.
     Schizophr Res. 2024;267:444-450.
     PubMed     Abstract available
     
     
     
467. LE BARS T, Bulteau S, Bonnot O, Gollier-Briant F, et al
     Home-based transcranial direct current stimulation in schizophrenia: Systematic literature review, a teenager case report with cost-utility analysis.
     Schizophr Res. 2024;267:441-443.
     PubMed    
     
     
     
468. GOGOS A, Sbisa A, van den Buuse M
     Disruption of NMDA receptor-mediated regulation of PPI in the maternal immune activation model of schizophrenia is restored by 17beta-estradiol and raloxifene.
     Schizophr Res. 2024;267:432-440.
     PubMed     Abstract available
     
     
     
469. AL-CHALABI N, Nader G, Gerretsen P, Fischer C, et al
     Assessing past suicidal behaviour in schizophrenia spectrum disorders using the Columbia-Suicide Severity Rating Scale and the Beck Scale for Suicide Ideation: Analysis across the life-span.
     Schizophr Res. 2024;267:415-421.
     PubMed     Abstract available
     
     
     
470. MOURA BM, Madeira L, Bakker PR, van Harten P, et al
     The association between alterations in motor and cognitive dimensions of schizophrenia-spectrum disorders: A systematic review.
     Schizophr Res. 2024;267:398-414.
     PubMed     Abstract available
     
     
     
471. HOLT DJ
     Personal space as a model neurobehavioral system for investigating schizophrenia.
     Schizophr Res. 2024;267:396-397.
     PubMed    
     
     
     
472. TOROUS J, Smith KA, Hardy A, Vinnikova A, et al
     Digital health interventions for schizophrenia: Setting standards for mental health.
     Schizophr Res. 2024;267:392-395.
     PubMed    
     
     
     
473. COHEN M, Roe D, Savir T, Baumel A, et al
     Blended care in psychosis - A systematic review.
     Schizophr Res. 2024;267:381-391.
     PubMed     Abstract available
     
     
     
474. TAKAHASHI T, Katagiri N, Higuchi Y, Nishiyama S, et al
     Nomenclature for psychosis risk in Japan: Survey results from high-risk individuals, caregivers, and mental health professionals.
     Schizophr Res. 2024;267:373-380.
     PubMed     Abstract available
     
     
     
475. CELLA M, Parri L, Wang K, Quinn R, et al
     Evaluating remote delivery of cognitive remediation in people with psychosis.
     Schizophr Res. 2024;267:367-372.
     PubMed     Abstract available
     
     
     
476. MOREIRA-ALMEIDA A, Costa MA, Gattaz WF
     Spiritist anomalous experience is not associated with psychosis.
     Schizophr Res. 2024;267:356-358.
     PubMed    
     
     
     
477. LANDOLT A, Muller M, Ilg Y, Schulz PJ, et al
     Linguistic and (micro)cultural differences in the global debate about re-naming 'schizophrenia': A mixed-methods survey from Switzerland.
     Schizophr Res. 2024;267:341-348.
     PubMed     Abstract available
     
     
     
478. ROCCA P, Brasso C, Montemagni C, Del Favero E, et al
     The relationship between the resting state functional connectivity and social cognition in schizophrenia: Results from the Italian Network for Research on Psychoses.
     Schizophr Res. 2024;267:330-340.
     PubMed     Abstract available
     
     
     
479. SHEITMAN A, Bello I, Montague E, Scodes J, et al
     Observed Trajectories of Cannabis Use and Concurrent Longitudinal Outcomes in Youth and Young Adults Receiving Coordinated Specialty Care for Early Psychosis.
     Schizophr Res. 2024;267:313-321.
     PubMed     Abstract available
     
     
     
480. GOUSE BM, Oblath R, Gibbs JS, Reagan EG, et al
     COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay.
     Schizophr Res. 2024;267:301-307.
     PubMed     Abstract available
     
     
     
481. DIAO H, Ma J, Jia Y, Jia H, et al
     Abnormalities in motor adaptation to different types of perturbations in schizophreniaperturbations in schizophrenia.
     Schizophr Res. 2024;267:291-300.
     PubMed     Abstract available
     
     
     
482. CATTARINUSSI G, Di Giorgio A, Sambataro F
     Cerebellar dysconnectivity in schizophrenia and bipolar disorder is associated with cognitive and clinical variables.
     Schizophr Res. 2024 Apr 6:S0920-9964(24)00139.
     PubMed     Abstract available
     
     
     
483. HO G, Pratt DN, Bridgwater MA, Schiffman J, et al
     Factors impacting intent to seek treatment within youth at clinical high risk for psychosis.
     Schizophr Res. 2024;267:273-281.
     PubMed     Abstract available
     
     
     
484. KANG MJY, Eratne D, Wannan C, Santillo AF, et al
     Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis.
     Schizophr Res. 2024;267:269-272.
     PubMed     Abstract available
     
     
     
485. SKLAR AL, Matinrazm S, Esseku A, Lopez-Caballero F, et al
     Intensity-dependent modulation of the early auditory gamma-band response in first-episode schizophrenia and its association with disease symptoms.
     Schizophr Res. 2024;267:261-268.
     PubMed     Abstract available
     
     
     
486. MULLIGAN LD, Bojanic L, Hunt IM, Baird A, et al
     Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in England.
     Schizophr Res. 2024;267:254-260.
     PubMed     Abstract available
     
     
     
487. KISELY S, Arnautovska U, Siskind D, Warren N, et al
     Admissions for psychosis following agency-notified child maltreatment at 40-year-follow-up: Results from the Childhood Adversity and Lifetime Morbidity (CALM) cohort.
     Schizophr Res. 2024;267:247-253.
     PubMed     Abstract available
     
     
     
488. OPLER M, Negash S, Tatsumi K, Liu C, et al
     Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia.
     Schizophr Res. 2024;267:239-246.
     PubMed    
     
     
     
489. CEDERLOF E, Holm M, Taipale H, Tiihonen J, et al
     Antipsychotic medications and sleep problems in patients with schizophrenia.
     Schizophr Res. 2024;267:230-238.
     PubMed     Abstract available
     
     
     
490. VARDEN GJERDE K, Bartz-Johannessen C, Steen VM, Andreassen OA, et al
     Cellular adhesion molecules in drug-naive and previously medicated patients with schizophrenia-spectrum disorders.
     Schizophr Res. 2024;267:223-229.
     PubMed     Abstract available
     
     
     
491. BISMARK AW, Mikhael T, Mitchell K, Holden J, et al
     Pupillary responses as a biomarker of cognitive effort and the impact of task difficulty on reward processing in schizophrenia.
     Schizophr Res. 2024;267:216-222.
     PubMed     Abstract available
     
     
     
492. FRANCO-RUBIO L, Puente-Martinez A, Ubillos-Landa S
     Factors associated with recovery during schizophrenia and related disorders: A review of meta-analysis.
     Schizophr Res. 2024;267:201-212.
     PubMed     Abstract available
     
     
     
493. LI Y, Qiu D, Wu Q, Ni A, et al
     Affiliate stigma and its association with family burden among family members of people living with schizophrenia in China.
     Schizophr Res. 2024;267:193-200.
     PubMed     Abstract available
     
     
     
494. FUJITA K, Mori Y, Kakumae Y, Takeuchi N, et al
     Pre-emptive ice pack cryotherapy for reducing pain caused by long-acting deltoid injectable antipsychotic treatment: A single-center open-label study.
     Schizophr Res. 2024;266:19-23.
     PubMed     Abstract available
     
     
     March 2024
495. COHEN-LAROQUE J, Grangier I, Perez N, Kirschner M, et al
     Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2024;267:182-190.
     PubMed     Abstract available
     
     
     
496. DODD K, Legget KT, Cornier MA, Novick AM, et al
     Relationship between functional connectivity and weight-gain risk of antipsychotics in schizophrenia.
     Schizophr Res. 2024;267:173-181.
     PubMed     Abstract available
     
     
     
497. GAO YN, Wang R, Gu G, Chung R, et al
     Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders.
     Schizophr Res. 2024;267:165-172.
     PubMed     Abstract available
     
     
     
498. YU B, Sun Z, Li S, Chien IC, et al
     Social isolation and cognitive function in patients with schizophrenia: A two years follow-up study.
     Schizophr Res. 2024;267:150-155.
     PubMed     Abstract available
     
     
     
499. BENNETT ME, Medoff D, Cowan T, Fang L, et al
     Tobacco smoking and nicotine vaping in persons with first episode psychosis.
     Schizophr Res. 2024;267:141-149.
     PubMed     Abstract available
     
     
     
500. PELIZZA L, Leuci E, Leucci AC, Quattrone E, et al
     Diagnostic shift in first episode psychosis: Results from the 2-year follow-up of the "Parma Early Psychosis" program.
     Schizophr Res. 2024;267:99-106.
     PubMed     Abstract available
     
     
     
501. MEHTA DD, Siddiqui S, Ward HB, Steele VR, et al
     Functional and structural effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal hallucinations in schizophrenia: A systematic review.
     Schizophr Res. 2024;267:86-98.
     PubMed     Abstract available
     
     
     
502. LHO SK, Kim T, Moon SY, Kim M, et al
     Alteration in left frontoparietal connectivity correlates with impaired cognitive reappraisal in early psychosis.
     Schizophr Res. 2024;267:130-137.
     PubMed     Abstract available
     
     
     
503. ZHOU R, Ye M, OuYang X, Zhang S, et al
     Insomnia and aggression in stable schizophrenic patients: The mediating role of quality of life.
     Schizophr Res. 2024;267:122-129.
     PubMed     Abstract available
     
     
     
504. ELAM HB, Perez SM, Donegan JJ, Eassa NE, et al
     Knockdown of Lhx6 during embryonic development results in neurophysiological alterations and behavioral deficits analogous to schizophrenia in adult rats.
     Schizophr Res. 2024;267:113-121.
     PubMed     Abstract available
     
     
     
505. EL HAJ M, Raffard S, Besche-Richard C
     Decoding schizophrenia: ChatGPT's role in clinical and neuropsychological assessment.
     Schizophr Res. 2024;267:84-85.
     PubMed    
     
     
     
506. NAIR N, Xavier S, Rabouin D, Mohan G, et al
     Patient-reported outcome measures in early psychosis: A cross-cultural, longitudinal examination of the self-reported health and self-reported mental health measures in Chennai, India and Montreal, Canada.
     Schizophr Res. 2024;267:75-83.
     PubMed     Abstract available
     
     
     
507. ARSLAN B, Kizilay E, Verim B, Demirlek C, et al
     Automated linguistic analysis in speech samples of Turkish-speaking patients with schizophrenia-spectrum disorders.
     Schizophr Res. 2024;267:65-71.
     PubMed     Abstract available
     
     
     
508. OZER D, Dissiz M
     The effect of online group based acceptance and commitment therapy on psychotic symptoms and functioning levels of individuals with early psychosis.
     Schizophr Res. 2024;267:55-64.
     PubMed     Abstract available
     
     
     
509. MELVIN E, Green M, Keiller E, Parmar C, et al
     A systematic review of dramatherapy interventions used to support adults with psychosis.
     Schizophr Res. 2024;267:44-54.
     PubMed     Abstract available
     
     
     
510. TZARTOS J, Karagiorgou K, Pechlivanidou M, Tzartos S, et al
     Absence of neuronal nicotinic acetylcholine receptor antibodies in sera and CSF from schizophrenia patients.
     Schizophr Res. 2024;267:39-41.
     PubMed    
     
     
     
511. KETCHAM E, Schooler NR, Severe JB, Buckley PF, et al
     Longitudinal study of insomnia, suicidal ideation, and psychopathology in schizophrenia.
     Schizophr Res. 2024;267:34-38.
     PubMed     Abstract available
     
     
     
512. JOLLY AJ, Parmar A, Ghadigaonkar DS, Andrade C, et al
     Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia.
     Schizophr Res. 2024;267:32-33.
     PubMed    
     
     
     
513. LLORCA-BOFI V, Madero S, Amoretti S, Cuesta MJ, et al
     Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia.
     Schizophr Res. 2024;267:24-31.
     PubMed     Abstract available
     
     
     
514. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
     Self-assessment scale of auditory verbal hallucinations (SAVH): A novel tool for patients with schizophrenia.
     Schizophr Res. 2024;267:19-23.
     PubMed     Abstract available
     
     
     
515. DYKINS MM, Keedy SK, Sweeney JA, Hill SK, et al
     Characterizing cognitive heterogeneity in first-episode psychosis.
     Schizophr Res. 2024;267:16-18.
     PubMed    
     
     
     
516. MCLEAN RT, Buist E, St Clair D, Wei J, et al
     Autoantibodies against acetylcholine receptors are increased in archived serum samples from patients with schizophrenia.
     Schizophr Res. 2024;267:8-13.
     PubMed     Abstract available
     
     
     
517. LI S, Liu W, Huang Z, Lin H, et al
     Sex-specific associations between sex hormones and clinical symptoms in late-life schizophrenia.
     Schizophr Res. 2024;267:1-7.
     PubMed     Abstract available
     
     
     
518. LE TP, Ventura J, Subotnik KL, Nuechterlein KH, et al
     Intrinsic motivation predicts cognitive and functional gains during coordinated specialty care for first-episode schizophrenia.
     Schizophr Res. 2024;266:249-255.
     PubMed     Abstract available
     
     
     
519. SLOT MIE, van Hell HH, Rossum IW, Dazzan P, et al
     A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.
     Schizophr Res. 2024;266:237-248.
     PubMed     Abstract available
     
     
     
520. KING B, Kempton MJ, Broberg BV, Merritt K, et al
     A letter to the editor: The effects of alcohol use on brain glutamate in first episode psychosis.
     Schizophr Res. 2024;266:234-236.
     PubMed    
     
     
     
521. STEPHANE M, Dzemidzic M, Yoon G
     Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study.
     Schizophr Res. 2024;265:14-19.
     PubMed     Abstract available
     
     
     
522. LOPEZ-SILVA P, Harrow M, Jobe TH, Tufano M, et al
     'Are these my thoughts?': A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations.
     Schizophr Res. 2024;265:46-57.
     PubMed     Abstract available
     
     
     February 2024
523. GARCIA-RIZO C, Crespo-Facorro B, Oliveira C, Gomez-Revuelta M, et al
     Anthropometry in antipsychotic-naive first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples.
     Schizophr Res. 2024;266:216-226.
     PubMed     Abstract available
     
     
     
524. ZAHER F, Diallo M, Achim AM, Joober R, et al
     Speech markers to predict and prevent recurrent episodes of psychosis: A narrative overview and emerging opportunities.
     Schizophr Res. 2024;266:205-215.
     PubMed     Abstract available
     
     
     
525. ISAYEVA U, Manchia M, Collu R, Primavera D, et al
     Symptomatic remission and recovery in major psychosis: Is there a role for BDNF? A secondary analysis of the LABSP cohort data.
     Schizophr Res. 2024;266:197-204.
     PubMed     Abstract available
     
     
     
526. SAVILL M, Loewy RL, Niendam TA, Porteus AJ, et al
     The diagnostic accuracy of screening for psychosis spectrum disorders in behavioral health clinics integrated into primary care.
     Schizophr Res. 2024;266:190-196.
     PubMed     Abstract available
     
     
     
527. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
     Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers.
     Schizophr Res. 2024;266:183-189.
     PubMed     Abstract available
     
     
     
528. ZHAO W, Cannon TD
     Moral learning and positive schizotypy: Social cognitive mechanisms in psychosis- proneness.
     Schizophr Res. 2024;266:156-164.
     PubMed     Abstract available
     
     
     
529. BAKER SC, Messer SJ, Girgis RR, Horga G, et al
     Prior overweighting relates to delusional ideation in individuals at clinical high-risk for psychosis.
     Schizophr Res. 2024;266:153-155.
     PubMed    
     
     
     
530. TIBIRICA L, Kohn J, Patapoff M, Williams AP, et al
     Acculturation and clinical symptoms of schizophrenia among Latine adults in the United States.
     Schizophr Res. 2024;266:145-152.
     PubMed     Abstract available
     
     
     
531. PENG Z, Li Q, Liu X, Zhang H, et al
     A new schizophrenia screening instrument based on evaluating the patient's writing.
     Schizophr Res. 2024;266:127-135.
     PubMed     Abstract available
     
     
     
532. MAKIPELTO V, Tuulio-Henriksson A, Hakulinen C, Niemela S, et al
     Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
     Schizophr Res. 2024;266:118-126.
     PubMed     Abstract available
     
     
     
533. BALLERINI M, Magnani F, Amorosi S, Dell'Anna C, et al
     Anomalous Self-Experiences are predictive of social dysfunction in people with schizophrenia.
     Schizophr Res. 2024;266:116-117.
     PubMed    
     
     
     
534. TORREGROSSA LJ, Liu J, Armstrong K, Heckers S, et al
     Interplay between childhood trauma, bodily self-disturbances, and clinical phenomena in schizophrenia spectrum disorders: A network analysis.
     Schizophr Res. 2024;266:107-115.
     PubMed     Abstract available
     
     
     
535. MILEY K, Bronstein MV, Ma S, Lee H, et al
     Trajectories and predictors of response to social cognition training in people with schizophrenia: A proof-of-concept machine learning study.
     Schizophr Res. 2024;266:92-99.
     PubMed     Abstract available
     
     
     
536. IMAM I, Johnson KA, Saluja A, Mesholam-Gately RI, et al
     Advancing equity & access for psychosis care in Massachusetts: Proceedings from the 2023 Mass-STEP Conference.
     Schizophr Res. 2024;266:85-87.
     PubMed    
     
     
     
537. GURUSAMY J, Gandhi S, Damodharan D, Palaniappan M, et al
     Effect of lifestyle modification intervention (LMI) on metabolic syndrome in schizophrenia in a residential mental health care setting-A mixed method study.
     Schizophr Res. 2024;266:75-84.
     PubMed    
     
     
     
538. ZAKI JK, Lago SG, Spadaro B, Rustogi N, et al
     Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia.
     Schizophr Res. 2024;266:66-74.
     PubMed     Abstract available
     
     
     
539. BORA E, Eyuboglu MS, Cesim E, Demir M, et al
     Neurocognition and social cognition in youth and young adults at ultra-high-risk for psychosis and bipolar disorder.
     Schizophr Res. 2024;266:58-65.
     PubMed     Abstract available
     
     
     
540. GARCIA-LEON MA, Fuentes-Claramonte P, Soler-Vidal J, Ramiro-Sousa N, et al
     Cortical volume abnormalities in schizophrenia: Correlations with symptoms and cognitive impairment.
     Schizophr Res. 2024;266:50-57.
     PubMed     Abstract available
     
     
     
541. EKIN M, Akdal G, Bora E
     Antisaccade error rates in first-episode psychosis, ultra-high risk for psychosis and unaffected relatives of schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2024;266:41-49.
     PubMed     Abstract available
     
     
     
542. MAAS IL, Bohlken MM, Gangadin SS, Rosema BS, et al
     Personal recovery in first-episode psychosis: Beyond clinical and functional recovery.
     Schizophr Res. 2024;266:32-40.
     PubMed     Abstract available
     
     
     
543. WARREN N, O'Gorman C, Horgan I, Weeratunga M, et al
     Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants.
     Schizophr Res. 2024;266:24-31.
     PubMed     Abstract available
     
     
     
544. CHANEN AM, Kerslake R, Berube FA, Nicol K, et al
     Psychopathology and psychosocial functioning among young people with first-episode psychosis and/or first-presentation borderline personality disorder.
     Schizophr Res. 2024;266:12-18.
     PubMed     Abstract available
     
     
     
545. KRAUS J, Cavojska N, Harvanova S, Hajduk M, et al
     Interpersonal distance in schizophrenia: A systematic review.
     Schizophr Res. 2024;266:1-11.
     PubMed     Abstract available
     
     
     
546. MCILWAINE SV, Mughal S, Ferrari M, Rosengard R, et al
     Pre-onset subthreshold psychotic symptoms are associated with differential treatment delays before a first episode of psychosis: Initial evidence and implications.
     Schizophr Res. 2024;264:549-556.
     PubMed     Abstract available
     
     
     
547. JEYAPALAN J, Sassi P, Mittendorfer Rutz E, Tiihonen J, et al
     Characteristics of incident substance-induced psychosis compared to first-episode psychotic disorders: A nationwide register-linkage study from Sweden.
     Schizophr Res. 2024;264:526-533.
     PubMed    
     
     
     
548. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
     The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study.
     Schizophr Res. 2024;264:386-393.
     PubMed     Abstract available
     
     
     January 2024
549. WANG Y, Ding R, Luo Y, He P, et al
     Does college education reduce the risk of schizophrenia? Evidence from a college enrollment expansion policy in China.
     Schizophr Res. 2024;264:519-525.
     PubMed     Abstract available
     
     
     
550. TORDAI C, Hathy E, Gyergyak H, Vincze K, et al
     Probing the biological consequences of a previously undescribed de novo mutation of ZMYND11 in a schizophrenia patient by CRISPR genome editing and induced pluripotent stem cell based in vitro disease-modeling.
     Schizophr Res. 2024 Jan 29:S0920-9964(24)00024.
     PubMed     Abstract available
     
     
     
551. KANE JM, Schoretsanitis G, Rubio JM, Correll CU, et al
     Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond.
     Schizophr Res. 2024 Jan 29:S0920-9964(24)00035.
     PubMed    
     
     
     
552. FADEN J, Citrome L
     A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder.
     Schizophr Res. 2024 Jan 29:S0920-9964(23)00420.
     PubMed     Abstract available
     
     
     
553. LOZANO-GOUPIL J, Marin L, Aubin L, Decombe A, et al
     Impaired perception of a partner's synchronizing behavior reduces positive attitude toward humanoid robot in schizophrenia patients.
     Schizophr Res. 2024;264:511-518.
     PubMed     Abstract available
     
     
     
554. MACDOUGALL AG, Wiener JC, Puka K, Price E, et al
     Effectiveness of a mindfulness-based intervention for persons with early psychosis: A multi-site randomized controlled trial.
     Schizophr Res. 2024;264:502-510.
     PubMed     Abstract available
     
     
     
555. MURPHY SM, Flores AT, Wojtalik JA, Keshavan MS, et al
     Symptom contributors to quality of life in schizophrenia: Exploratory factor and network analyses.
     Schizophr Res. 2024;264:494-501.
     PubMed     Abstract available
     
     
     
556. ESCANDON K
     Toward non-stigmatizing media and language in mental health: Addressing the social stigma of schizophrenia.
     Schizophr Res. 2024;264:491-493.
     PubMed    
     
     
     
557. ZEDAN SA, Zahid A, Best MW
     Examining the effects of diagnostic awareness, positive symptoms, and negative symptoms on stigmatizing attitudes and social exclusion towards schizophrenia.
     Schizophr Res. 2024;264:482-490.
     PubMed     Abstract available
     
     
     
558. BHARGAV H, Keshavan M
     Why and how might yoga differ from other mind-body approaches in schizophrenia?
     Schizophr Res. 2024;264:479-481.
     PubMed    
     
     
     
559. VAN DER PLUIJM M, Alting M, Schrantee A, Edden RAE, et al
     Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.
     Schizophr Res. 2024;264:471-478.
     PubMed     Abstract available
     
     
     
560. LIU H, Tang E, Guan C, Li J, et al
     Not socially blind: Unimpaired perception of social interaction in schizophrenia.
     Schizophr Res. 2024;264:448-450.
     PubMed    
     
     
     
561. GRADY S, Twomey C, Cullen C, Gaynor K, et al
     Does affect mediate the relationship between interpersonal trauma and psychosis? A systematic review and meta-analysis.
     Schizophr Res. 2024;264:435-447.
     PubMed     Abstract available
     
     
     
562. D'ARCEY JN, Zhao H, Wang W, Voineskos AN, et al
     An SMS text messaging intervention to improve clinical engagement in early psychosis: A pilot randomized-controlled trial.
     Schizophr Res. 2024;264:416-423.
     PubMed     Abstract available
     
     
     
563. CHEN MY, Wang YY, Si TL, Liu YF, et al
     Poor sleep quality in schizophrenia patients: A systematic review and meta-analyses of epidemiological and case-control studies.
     Schizophr Res. 2024;264:407-415.
     PubMed     Abstract available
     
     
     
564. CAI Y, Zhu ZH, Qi Q, Yin XY, et al
     The negative association of serum complement 3 and 4 levels with visuospatial/constructional function in first-episode patients with schizophrenia.
     Schizophr Res. 2024;264:404-406.
     PubMed    
     
     
     
565. SHANKAR A, Tripathi A
     Comments on "The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A
     Schizophr Res. 2024;264:402-403.
     PubMed    
     
     
     
566. NG BHM, Yu BCL, Leung JSY
     Investigation on the association between perceived family expressed emotion, self-stigma, and subjective quality of life in people with early psychosis in Hong Kong: A cross-sectional approach.
     Schizophr Res. 2024;264:394-401.
     PubMed    
     
     
     
567. GHIEH R, Krezolek M, Gaweda L
     Self-monitoring deficits in schizophrenia: A cross-sectional study of the underlying cognitive mechanisms.
     Schizophr Res. 2024;264:378-385.
     PubMed     Abstract available
     
     
     
568. LAWRENCE RE, Appelbaum PS
     Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks.
     Schizophr Res. 2024;264:372-377.
     PubMed     Abstract available
     
     
     
569. BOWERSOX NW, Smith CM, Austin K, Bradford DW, et al
     Mortality and suicidality in veterans health administration patients with newly-identified early episode psychosis.
     Schizophr Res. 2024;264:362-369.
     PubMed     Abstract available
     
     
     
570. SONDERGAARD A, Gregersen M, Wilms M, Brandt JM, et al
     Exploring the relationship between attributional style measured in virtual reality and bullying among children at familial high risk of schizophrenia or bipolar disorder compared with controls.
     Schizophr Res. 2024;264:354-361.
     PubMed     Abstract available
     
     
     
571. THAKKAR KN, Silverstein SM, Fattal J, Bao J, et al
     Stronger tilt aftereffects in individuals diagnosed with schizophrenia spectrum disorders but not bipolar disorder.
     Schizophr Res. 2024;264:345-353.
     PubMed     Abstract available
     
     
     
572. PENTZ AB, O'Connel KS, van Jole O, Timpe CMF, et al
     Mismatch negativity and polygenic risk scores for schizophrenia and bipolar disorder.
     Schizophr Res. 2024;264:314-326.
     PubMed     Abstract available
     
     
     
573. IBRAHIM K, Iturmendi-Sabater I, Vasishth M, Barron DS, et al
     Neural circuit disruptions of eye gaze processing in autism spectrum disorder and schizophrenia: An activation likelihood estimation meta-analysis.
     Schizophr Res. 2024;264:298-313.
     PubMed     Abstract available
     
     
     
574. WANG P, Jiang Y, Biswal BB
     Aberrant interhemispheric structural and functional connectivity within whole brain in schizophrenia.
     Schizophr Res. 2024;264:336-344.
     PubMed     Abstract available
     
     
     
575. OKADA H, Morimoto T, Ikeda N
     Exploratory; study on driving ability of people with schizophrenia: Relationships among cognitive function, symptoms, and brain activity.
     Schizophr Res. 2024;264:290-297.
     PubMed     Abstract available
     
     
     
576. XIONG J, Ding Y, Wu X, Zhan J, et al
     Association between serum insulin-like growth factor 1 levels and the improvements of cognitive impairments in a subgroup of schizophrenia: Preliminary findings.
     Schizophr Res. 2024;264:282-289.
     PubMed     Abstract available
     
     
     
577. DEAM MM, Gupta T, Bridgwater MA, Haas GL, et al
     Associations between interpersonal trauma and social impairments in adolescents with and without a family history of psychosis.
     Schizophr Res. 2024;264:280-281.
     PubMed    
     
     
     
578. CHEN YL, Chen PY, Pan CH, Chen PH, et al
     Prevalence and 3-year incidence of physical illnesses after schizophrenia diagnosis: Comparison with general population.
     Schizophr Res. 2024;264:272-279.
     PubMed     Abstract available
     
     
     
579. DONMEZLER S, Sonmez D, Yilbas B, Ozturk HI, et al
     Thalamic nuclei volume differences in schizophrenia patients and healthy controls using probabilistic mapping: A comparative analysis.
     Schizophr Res. 2024;264:266-271.
     PubMed     Abstract available
     
     
     
580. SU Y, Pan X, Li H, Zhang G, et al
     Effects of mind-body therapies on schizophrenia: A systematic review and network meta-analysis.
     Schizophr Res. 2024;264:236-247.
     PubMed     Abstract available
     
     
     
581. MILLER M, Braun A, Cadenhead KS, Cornblatt BA, et al
     Self-perceptions and depression in youth at risk of psychosis.
     Schizophr Res. 2024;264:231-232.
     PubMed    
     
     
     
582. CHANG Y, Wang X, Liao J, Chen S, et al
     Temporal hyper-connectivity and frontal hypo-connectivity within gamma band in schizophrenia: A resting state EEG study.
     Schizophr Res. 2024;264:220-230.
     PubMed     Abstract available
     
     
     
583. LEGRAND A, Moyal M, Deschamps C, Louveau C, et al
     Catatonia and genetic variant in GABA receptor: A case report involving GABRB2.
     Schizophr Res. 2024;263:191-193.
     PubMed    
     
     
     
584. KARL S, Sartorius A, Aksay SS
     Catatonia and ECT across the lifespan.
     Schizophr Res. 2024;263:246-251.
     PubMed     Abstract available
     
     
     
585. HIRJAK D, Brandt GA, Fritze S, Kubera KM, et al
     Distribution and frequency of clinical criteria and rating scales for diagnosis and assessment of catatonia in different study types.
     Schizophr Res. 2024;263:93-98.
     PubMed     Abstract available
     
     
     
586. WADDINGTON JL
     From operational diagnostic to dimensional-continuum concepts of psychotic and non-psychotic illness: Embracing catatonia across psychopathology and intrinsic movement disorder in neural network dysfunction.
     Schizophr Res. 2024;263:99-108.
     PubMed     Abstract available
     
     
     
587. SAINI A, Begum N, Matti J, Ghanem DA, et al
     Clozapine as a treatment for catatonia: A systematic review.
     Schizophr Res. 2024;263:275-281.
     PubMed     Abstract available
     
     
     December 2023
588. KLAASSEN AL, Michel C, Stuble M, Kaess M, et al
     Reduced anterior callosal white matter in risk for psychosis associated with processing speed as a fundamental cognitive impairment.
     Schizophr Res. 2023;264:211-219.
     PubMed     Abstract available
     
     
     
589. RASMUSSEN AR
     Anomalies of imagination and development of psychosis: A phenomenological account.
     Schizophr Res. 2023;264:204-210.
     PubMed     Abstract available
     
     
     
590. SABE M, Kohler R, Perez N, Sauvain-Sabe M, et al
     Mindfulness-based interventions for patients with schizophrenia spectrum disorders: A systematic review of the literature.
     Schizophr Res. 2023;264:191-203.
     PubMed     Abstract available
     
     
     
591. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
     A digital tool for self-assessment of auditory verbal hallucinations in schizophrenia.
     Schizophr Res. 2023;264:188-190.
     PubMed     Abstract available
     
     
     
592. MYERS EJ, Abel DB, Mickens JL, Russell MT, et al
     Meta-analysis of the relationship between metacognition and disorganized symptoms in psychosis.
     Schizophr Res. 2023;264:178-187.
     PubMed     Abstract available
     
     
     
593. MELZER-RIBEIRO DL, Napolitano IC, Leite SA, Alencar de Souza JA, et al
     Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia.
     Schizophr Res. 2023 Dec 26:S0920-9964(23)00421.
     PubMed     Abstract available
     
     
     
594. BAHLINGER K, Lincoln TM, Clamor A
     Do deficits in subjective stress recovery predict subsequent stress sensitivity and symptoms in schizophrenia spectrum disorders?
     Schizophr Res. 2023;264:170-177.
     PubMed     Abstract available
     
     
     
595. ZINELLU A, Mangoni AA
     The pathophysiological role of circulating adhesion molecules in schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2023;264:157-169.
     PubMed     Abstract available
     
     
     
596. BARBALAT G, Marechal L, Plasse J, Chereau-Boudet I, et al
     Functioning, clinical severity, education and sex moderate the inverse relationship between insight and quality of life in patients with schizophrenia.
     Schizophr Res. 2023;264:149-156.
     PubMed     Abstract available
     
     
     
597. TROISI A, Brune M
     The ethological method for studying facial behavior in schizophrenia.
     Schizophr Res. 2023;264:147-148.
     PubMed    
     
     
     
598. HYATT A, Mullin B, Hasler V, Madore D, et al
     Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis.
     Schizophr Res. 2023;264:140-146.
     PubMed     Abstract available
     
     
     
599. JI Y, Pearlson G, Bustillo J, Kochunov P, et al
     Identifying psychosis subtypes use individualized covariance structural differential networks and multi-site clustering.
     Schizophr Res. 2023;264:130-139.
     PubMed     Abstract available
     
     
     
600. HUANG TY, Chen LC, Li XP, Li WH, et al
     Elevated triglycerides and low triiodothyronine: Key risk factors for coronary artery calcification in patients with schizophrenia.
     Schizophr Res. 2023;264:113-121.
     PubMed     Abstract available
     
     
     
601. DONDE C, Coulon N, Turbe H, Andre M, et al
     Clinical and cognitive characteristics of subjects with schizophrenia and childhood attention-deficit/hyperactivity disorder: Results from the multicentric FACE-SZ cross-sectional dataset.
     Schizophr Res. 2023;264:105-112.
     PubMed     Abstract available
     
     
     
602. MORERA D, Miller BJ
     Meta-analysis of a family history of diabetes in schizophrenia.
     Schizophr Res. 2023;264:90-94.
     PubMed     Abstract available
     
     
     
603. GUAN X, Chen Y, Wang X, Xiu M, et al
     Total antioxidant capacity, obesity and clinical correlates in first-episode and drug-naive patients with schizophrenia.
     Schizophr Res. 2023;264:81-86.
     PubMed     Abstract available
     
     
     
604. SAPIENZA J, Agostoni G, Dall'Acqua S, Sut S, et al
     The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy.
     Schizophr Res. 2023;264:71-80.
     PubMed     Abstract available
     
     
     
605. BOIKO DI, Chopra H, Bilal M, Kydon PV, et al
     Schizophrenia and disruption of circadian rhythms: An overview of genetic, metabolic and clinical signs.
     Schizophr Res. 2023;264:58-70.
     PubMed     Abstract available
     
     
     
606. LIEBRAND M, Katsarakis A, Josi J, Diezig S, et al
     EEG microstate D as psychosis-specific correlate in adolescents and young adults with clinical high risk for psychosis and first-episode psychosis.
     Schizophr Res. 2023;264:49-57.
     PubMed     Abstract available
     
     
     
607. CADENHEAD KS, Mirzakhanian H, Achim C, Reyes-Madrigal F, et al
     Peripheral and central biomarkers associated with inflammation in antipsychotic naive first episode psychosis: Pilot studies.
     Schizophr Res. 2023;264:39-48.
     PubMed     Abstract available
     
     
     
608. LIU S, Zhang L, Fan X, Wang G, et al
     Lactate levels in the brain and blood of schizophrenia patients: A systematic review and meta-analysis.
     Schizophr Res. 2023;264:29-38.
     PubMed     Abstract available
     
     
     
609. TANDON R, Nasrallah H, Akbarian S, Carpenter WT Jr, et al
     The schizophrenia syndrome, circa 2024: What we know and how that informs its nature.
     Schizophr Res. 2023;264:1-28.
     PubMed     Abstract available
     
     
     
610. GARCIA-MARTI G, Escarti MJ, Nacher J, Perez-Rando M, et al
     Progressive loss of cortical gray matter in first episode psychosis patients with auditory hallucinations.
     Schizophr Res. 2023 Dec 2:S0920-9964(23)00423.
     PubMed     Abstract available
     
     
     
611. LE TP, Green MF, Wynn JK, Iglesias JE, et al
     Effort-based decision-making as a determinant of supported employment outcomes in psychotic disorders.
     Schizophr Res. 2023;262:149-155.
     PubMed     Abstract available
     
     
     
612. VIROLLE J, Redon M, Montastruc F, Taib S, et al
     What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.
     Schizophr Res. 2023;262:184-200.
     PubMed     Abstract available
     
     
     November 2023
613. YU S, Qu Y, Du Z, Ou M, et al
     The expression of immune related genes and potential regulatory mechanisms in schizophrenia.
     Schizophr Res. 2023 Nov 21:S0920-9964(23)00419.
     PubMed     Abstract available
     
     
     
614. SCHAUG JP, Storebo OJ, Pedersen MB, Haahr UH, et al
     How first-episode psychosis patients' subjective beliefs about their childhood trauma's causal effect provide support for potential schizophrenia subtypes.
     Schizophr Res. 2023;262:175-183.
     PubMed     Abstract available
     
     
     
615. FU X, Baranova A, Cao H, Liu Y, et al
     miR-9-5p deficiency contributes to schizophrenia.
     Schizophr Res. 2023;262:168-174.
     PubMed     Abstract available
     
     
     
616. TANG W, Zhou LJ, Zhang WQ, Jia YJ, et al
     Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis.
     Schizophr Res. 2023;262:156-167.
     PubMed     Abstract available
     
     
     
617. DEL RE EC, Keshavan MS
     Childhood trauma and psychosis-Searching for causes and mechanisms.
     Schizophr Res. 2023;262:146-148.
     PubMed    
     
     
     
618. VAN HOOIJDONK CFM, van der Pluijm M, de Vries BM, Cysouw M, et al
     The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia: A machine-learning-based approach.
     Schizophr Res. 2023;262:132-141.
     PubMed     Abstract available
     
     
     
619. MOE AM, Kilicoglu MFV, Angers K, Huang K, et al
     Coordinated specialty care for first-episode psychosis: Effects on social motivation and social pleasure.
     Schizophr Res. 2023;262:130-131.
     PubMed    
     
     
     
620. EL KIRAT H, Khattabi A, Khalis M, Belrhiti Z, et al
     Effects of physical activity and nutrient supplementation on symptoms and well-being of schizophrenia patients: An umbrella review.
     Schizophr Res. 2023;262:112-120.
     PubMed     Abstract available
     
     
     
621. TIEN YT, Wang LJ, Lee Y, Lin PY, et al
     Comparative predictive efficacy of atherogenic indices on metabolic syndrome in patients with schizophrenia.
     Schizophr Res. 2023;262:95-101.
     PubMed     Abstract available
     
     
     
622. BURKE T, Holleran L, Mothersill D, Lyons J, et al
     Bilateral anterior corona radiata microstructure organisation relates to impaired social cognition in schizophrenia.
     Schizophr Res. 2023;262:87-94.
     PubMed     Abstract available
     
     
     
623. XU S, Xu L
     Childhood emotional maltreatment increases the "wear-and-tear" of physiological systems, especially neuroendocrine changes in schizophrenia.
     Schizophr Res. 2023;262:84-86.
     PubMed    
     
     
     
624. STEENHUIS LA, Harms T, Nauta MH, Bartels-Velthuis AA, et al
     The dynamics of social activation and suspiciousness in individuals at ultra-high risk for psychosis.
     Schizophr Res. 2023;262:67-75.
     PubMed     Abstract available
     
     
     
625. BARUTH JM, Bateman DR, Kovacs RJ, Bateman PV, et al
     Cardiac healthcare disparities and electrocardiography (ECG) differences in schizophrenia at end of life.
     Schizophr Res. 2023;262:60-66.
     PubMed     Abstract available
     
     
     
626. OH H, Karcher NR, Schiffman J, Anglin DM, et al
     A broader conceptualization of premorbid risk in psychoses can motivate primordial prevention.
     Schizophr Res. 2023;262:53-54.
     PubMed    
     
     
     
627. PANIKRATOVA YR, Lebedeva IS, Akhutina TV, Tikhonov DV, et al
     Executive control of language in schizophrenia patients with history of auditory verbal hallucinations: A neuropsychological and resting-state fMRI study.
     Schizophr Res. 2023 Nov 1:S0920-9964(23)00388.
     PubMed     Abstract available
     
     
     
628. HAHN B, Holzel ES
     Nicotine insensitivity and cue-controlled smoking behavior in people with schizophrenia.
     Schizophr Res. 2023;262:51-52.
     PubMed    
     
     
     
629. EACK SM, Wojtalik JA, Keshavan MS
     Anticholinergic medications in the treatment of psychoses: Pharmacological subtraction is better than addition.
     Schizophr Res. 2023;262:40-41.
     PubMed    
     
     
     
630. RINCON-CORTES M, Grace AA
     Sex-dependent emergence of prepubertal social dysfunction and augmented dopamine activity in a neurodevelopmental rodent model relevant for schizophrenia.
     Schizophr Res. 2023;262:32-39.
     PubMed     Abstract available
     
     
     
631. VAZIRI N, Marques D, Greenway SC, Bousman CA, et al
     The cellular mechanism of antipsychotic-induced myocarditis: A systematic review.
     Schizophr Res. 2023;261:206-215.
     PubMed     Abstract available
     
     
     October 2023
632. WU X, Ao H, Wu X, Cao Y, et al
     Sulfur-containing amino acids and risk of schizophrenia.
     Schizophr Res. 2023;262:8-17.
     PubMed     Abstract available
     
     
     
633. CLAUSS-KOBAYASHI JME, Bonah C, Danion-Grilliat A, Scarfone M, et al
     Reshaping the diagnostic borders: Historical analysis of the diagnostic changes following the introduction of the schizophrenia concept.
     Schizophr Res. 2023;262:21-29.
     PubMed     Abstract available
     
     
     
634. STAINTON A, Cheng N, Bryce S, Dalton A, et al
     Cognition is a treatment priority for young people with psychosis: Findings from the Your Mind, Your Choice survey.
     Schizophr Res. 2023;262:30-31.
     PubMed    
     
     
     
635. LAMSMA J, Harte JM, Cahn W
     Risk factors for violent behaviour before and after the onset of schizophrenia spectrum disorder: A naturalistic case-control study in the Netherlands.
     Schizophr Res. 2023;262:1-7.
     PubMed     Abstract available
     
     
     
636. ROGERS E, Gresswell M, Durrant S
     The relationship between sleep and suicidality in schizophrenia spectrum and other psychotic disorders: A systematic review.
     Schizophr Res. 2023;261:291-303.
     PubMed     Abstract available
     
     
     
637. HUO L, Qu D, Pei C, Wu W, et al
     Alexithymia in chronic schizophrenia and its mediating effect between cognitive deficits and negative symptoms.
     Schizophr Res. 2023;261:275-280.
     PubMed     Abstract available
     
     
     
638. WILSON M, Harris M, Pereira M, Buckle J, et al
     Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
     Schizophr Res. 2023;261:269-274.
     PubMed     Abstract available
     
     
     
639. FERNANDEZ-ABASCAL B, Suarez-Pinilla M, Cobo-Corrales C, Crespo-Facorro B, et al
     Lifestyle intervention based on exercise and behavioural counselling and its effect on physical and psychological health in outpatients with schizophrenia spectrum disorders. An exploratory, pragmatic randomized clinical trial.
     Schizophr Res. 2023;261:256-268.
     PubMed     Abstract available
     
     
     
640. POORGANJI M, Goeke K, Zomorrodi R, Voineskos D, et al
     The use of theta burst stimulation in patients with schizophrenia - A systematic review.
     Schizophr Res. 2023;261:245-255.
     PubMed     Abstract available
     
     
     
641. BESTERMAN AD
     A genetics-guided approach to the clinical management of schizophrenia.
     Schizophr Res. 2023 Oct 7:S0920-9964(23)00353.
     PubMed     Abstract available
     
     
     
642. STONE WS, Phillips MR, Yang LH, Kegeles LS, et al
     Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).
     Schizophr Res. 2023;261:234-235.
     PubMed    
     
     
     
643. OLOGUNDUDU OM, Palaniyappan L, Cipriano LE, Wijnen BFM, et al
     Risk stratification for treating people at ultra-high risk for psychosis: A cost-effectiveness analysis.
     Schizophr Res. 2023;261:225-233.
     PubMed     Abstract available
     
     
     
644. LUTHER L, Westbrook A, Ayawvi G, Ruiz I, et al
     The role of defeatist performance beliefs on cognitive effort-cost decision-making in schizophrenia.
     Schizophr Res. 2023;261:216-224.
     PubMed     Abstract available
     
     
     
645. CHEUK NKW, Tse W, Tsui HKH, Ma CF, et al
     A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia.
     Schizophr Res. 2023 Oct 1:S0920-9964(23)00338.
     PubMed     Abstract available
     
     
     September 2023
646. KERKOVA B, Knizkova K, Vecerova M, Sustova P, et al
     Inflammation and cognitive performance in first-episode schizophrenia spectrum disorders: The moderating effects of childhood trauma.
     Schizophr Res. 2023;261:185-193.
     PubMed     Abstract available
     
     
     
647. PESA J, Liu Z, Fu AZ, Campbell AK, et al
     Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
     Schizophr Res. 2023;261:170-177.
     PubMed     Abstract available
     
     
     
648. HUANG LY, Parker DA, Ethridge LE, Hamm JP, et al
     Double dissociation between P300 components and task switch error type in healthy but not psychosis participants.
     Schizophr Res. 2023;261:161-169.
     PubMed     Abstract available
     
     
     
649. STEPHAN NM, van Sprang ED, Wiebenga JXM, Dickhoff J, et al
     Risk factors for suicidality across psychosis vulnerability spectrum.
     Schizophr Res. 2023;261:152-160.
     PubMed     Abstract available
     
     
     
650. KANG N, Kim SH, Kim J, Kim S, et al
     Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital.
     Schizophr Res. 2023 Sep 26:S0920-9964(23)00340.
     PubMed     Abstract available
     
     
     
651. OU M, Du Z, Jiang Y, Zhou Q, et al
     Causal relationship between schizophrenia and sex hormone binding globulin: A Mendelian randomization study.
     Schizophr Res. 2023 Sep 19:S0920-9964(23)00341.
     PubMed     Abstract available
     
     
     
652. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
     Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey.
     Schizophr Res. 2023 Sep 19:S0920-9964(23)00297.
     PubMed    
     
     
     
653. LI X, Lafit G, van Aubel E, Vaessen T, et al
     Emotion regulation in daily life in early psychosis: The role of contextual appraisals.
     Schizophr Res. 2023;261:130-138.
     PubMed     Abstract available
     
     
     
654. CHEN Q, Li X, Weng K, Zhang Y, et al
     Inflammatory mediators and the effect of electroconvulsive therapy in patients with schizophrenia.
     Schizophr Res. 2023;261:125-127.
     PubMed    
     
     
     
655. DAMIANI S, Zarbo C, Stolarski M, Zamparini M, et al
     Time will tell: Associations between unbalanced time perspectives and symptom severity in individuals with schizophrenia spectrum disorders.
     Schizophr Res. 2023;261:116-124.
     PubMed     Abstract available
     
     
     
656. HEGDE S, Keshavan MS
     The brain on the beat: How music may heal schizophrenia.
     Schizophr Res. 2023;261:113-115.
     PubMed    
     
     
     
657. ZHANG L, James SH, Strauss GP
     Environmental resource reductions predict greater severity of negative symptoms in schizophrenia.
     Schizophr Res. 2023;261:94-99.
     PubMed     Abstract available
     
     
     
658. PENTZ AB, Timpe CMF, Normann EM, Slapo NB, et al
     Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity.
     Schizophr Res. 2023;261:80-93.
     PubMed     Abstract available
     
     
     
659. GAUDIANO BA, Ellenberg S, Johnson JE, Mueser KT, et al
     Effectiveness of acceptance and commitment therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial.
     Schizophr Res. 2023;261:72-79.
     PubMed     Abstract available
     
     
     
660. QI W, Wen Z, Chen J, Capichioni G, et al
     Aberrant resting-state functional connectivity of the globus pallidus interna in first-episode schizophrenia.
     Schizophr Res. 2023;261:100-106.
     PubMed     Abstract available
     
     
     
661. SAUER A, Grent-'t-Jong T, Zeev-Wolf M, Singer W, et al
     Spectral and phase-coherence correlates of impaired auditory mismatch negativity (MMN) in schizophrenia: A MEG study.
     Schizophr Res. 2023;261:60-71.
     PubMed     Abstract available
     
     
     
662. GOVANI V, Shastry AM, Iosifescu DV, Govil P, et al
     Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
     Schizophr Res. 2023;260:205-208.
     PubMed    
     
     
     
663. SORIA BRETONES C, Roncero Parra C, Cascon J, Borja AL, et al
     Automatic identification of schizophrenia employing EEG records analyzed with deep learning algorithms.
     Schizophr Res. 2023;261:36-46.
     PubMed     Abstract available
     
     
     
664. MATSUI K, Kuriyama K, Yoshiike T, Kawamura A, et al
     Relapse of schizophrenia associated with comorbid delayed sleep-wake phase disorder but not with evening chronotype.
     Schizophr Res. 2023;261:34-35.
     PubMed    
     
     
     
665. PANCHAL Y, Gannon JM, Tatar JM, Balasubramani GK, et al
     COVID-19 vaccination among patients with schizophrenia prescribed clozapine.
     Schizophr Res. 2023;261:31-33.
     PubMed    
     
     
     
666. FERRARA M, Guloksuz S, Hazan H, Li F, et al
     The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service.
     Schizophr Res. 2023;260:198-204.
     PubMed     Abstract available
     
     
     
667. GOLAY P, Abrahamyan Empson L, Mebdouhi N, Conus P, et al
     A better understanding of the impact of childhood trauma on depression in early psychosis: A differential item functioning approach.
     Schizophr Res. 2023;261:18-23.
     PubMed     Abstract available
     
     
     
668. PATEL R, Chan KMY, Palmer EOC, Valko M, et al
     Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
     Schizophr Res. 2023;260:191-197.
     PubMed     Abstract available
     
     
     
669. SCHOTTLE D, Wiedemann K, Correll CU, Janetzky W, et al
     Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly.
     Schizophr Res. 2023;260:183-190.
     PubMed    
     
     
     
670. GANGADIN SS, Germann M, de Witte LD, Gelderman KA, et al
     Complement component 4A protein levels are negatively related to frontal volumes in patients with schizophrenia spectrum disorders.
     Schizophr Res. 2023;261:6-14.
     PubMed     Abstract available
     
     
     
671. HINKLEY LBN, Haas SS, Cheung SW, Nagarajan SS, et al
     Reduced neural connectivity in the caudate anterior head predicts hallucination severity in schizophrenia.
     Schizophr Res. 2023;261:1-5.
     PubMed     Abstract available
     
     
     
672. POLETTI M, Raballo A
     Subjective self-experiences at the mirror in patients with schizophrenia.
     Schizophr Res. 2023;260:180-182.
     PubMed    
     
     
     
673. WANG T, Codling D, Bhugra D, Msosa Y, et al
     Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.
     Schizophr Res. 2023;260:168-179.
     PubMed     Abstract available
     
     
     
674. ROBINSON N, Ploner A, Muller-Eberstein R, Lichtenstein P, et al
     Migration and risk of schizophrenia and bipolar disorder: A Swedish national study.
     Schizophr Res. 2023;260:160-167.
     PubMed     Abstract available
     
     
     
675. GRANRUD OE, Rodriguez Z, Cowan T, Masucci MD, et al
     Alogia and pressured speech do not fall on a continuum of speech production using objective speech technologies.
     Schizophr Res. 2023;259:121-126.
     PubMed     Abstract available
     
     
     August 2023
676. HONIGFELD G
     Clozapine in treatment-resistant schizophrenia: Who designed that famous US clinical trial?
     Schizophr Res. 2023 Aug 31:S0920-9964(23)00287.
     PubMed    
     
     
     
677. GRIFFITHS K, Smart SE, Barker GJ, Deakin B, et al
     Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia.
     Schizophr Res. 2023;260:152-159.
     PubMed     Abstract available
     
     
     
678. CLEMENTZ BA, Chattopadhyay I, Trotti RL, Parker DA, et al
     Clinical characterization and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)-1.
     Schizophr Res. 2023;260:143-151.
     PubMed     Abstract available
     
     
     
679. GOFF DC, Santacatterina M, Capichioni G, Ando F, et al
     Levetiracetam effects on hippocampal blood flow and symptoms in medication-free individuals with nonaffective first episode psychosis (letter).
     Schizophr Res. 2023;260:140-142.
     PubMed    
     
     
     
680. MUESER KT, Sussman RF, DeTore NR, Eberlin ES, et al
     The impact of early intervention for first episode psychosis on cognitive functioning.
     Schizophr Res. 2023;260:132-139.
     PubMed     Abstract available